documents incorporated reference specified portions registrants proxy statement filed commission pursuant regulation connection registrants annual meeting stockholders held may incorporated reference part iii report based closing price per share excludes shares registrants common stock held executive officers directors stockholders whose ownership exceeds common stock outstanding june exclusion shares construed indicate person possesses power direct indirect direct cause direction management policies registrant person controlled common control registranttable contents gilead sciences inc annual report table contents part item business item risk factors item b unresolved staff comments item properties item legal proceedings item submission matters vote security holders part ii item market registrants common equity related stockholder matters issuer purchases equity securities item selected financial data item managements discussion analysis financial condition results operations item quantitative qualitative disclosures market risk item financial statements supplementary data item changes disagreements accountants accounting financial disclosure item controls procedures item b information part iii item directors executive officers registrant item executive compensation item security ownership certain beneficial owners management related stockholder matters item certain relationships related transactions item principal accounting fees services part iv item exhibits financial statement schedules signatures rights various trademarks copyrights trade names used business including following gilead gilead sciences hepsera viread vistide daunoxome ambisome emtriva truvada macugen registered trademark belonging osi pharmaceuticals inc sustiva videx registered trademarks baraclude trademark bristolmyers squibb company tamiflu registered trademark belonging f hoffmannla roche ltd retrovir trizivir combivir registered trademarks epzicom trademark glaxosmithkline inc cancidas registered trademark belonging merck co inc report also includes trademarks service marks trade names companiestable contents annual report including managements discussion analysis financial condition results operations contains forward looking statements regarding future events future results subject safe harbors created securities act securities act securities exchange act exchange act words expect anticipate target goal project intend plan believe seek estimate continue may variations words similar expressions intended identify forwardlooking statements addition statements refer projections future financial performance anticipated growth trends businesses characterizations future events circumstances forwardlooking statements based forward looking statements current expectations future events statements guarantees future performance involve risks uncertainties assumptions difficult predict actual results may differ materially suggested forward looking statements various reasons including identified risk factors beginning given risks uncertainties cautioned place undue reliance forward looking statements forward looking statements included report made date hereof except required federal securities laws rules regulations us securities exchange commission sec undertake specifically decline obligation update statements publicly announce results revisions forward looking statements distribution report whether result new information future events changes assumptions otherwise part item business overview gilead sciences inc biopharmaceutical company discovers develops commercializes therapeutics advance care patients suffering lifethreatening diseases multinational company revenues nine approved products marketing operations twelve countries focus research clinical programs antiinfectives seek add existing portfolio products internal discovery clinical development programs active product acquisition inlicensing strategy used annual report gilead us words similar import references gilead sciences inc consolidated subsidiaries worldwide headquarters foster city california incorporated delaware june mailing address headquarters lakeside drive foster city california telephone number location website wwwgileadcom link investors section website financial information make available following filings soon reasonably practicable electronically filed furnished sec annual reports quarterly reports form q current reports form k amendments reports filed furnished pursuant section securities exchange act filings available free charge products viread tenofovir disoproxil fumarate oral formulation nucleotide analogue reverse transcriptase inhibitor dosed day part combination therapy treat human immunodeficiency virus hiv infection adults promote viread united states us commercial team sell united states exclusively wholesale channel promote sell viread major european countries european commercial team distributors certain latin american countries distributors promote sell viread japan corporate partner japan tobacco inc japan tobacco exclusive worldwide license patent rights related technology viread institute organic chemistry biochemistry part academy sciences czech republic rega stichting vzw together iocbrega table contents truvada emtricitabine tenofovir disoproxil fumarate oral formulation dosed day part combination therapy treat hiv infection adults fixeddose combination antihiv medications viread emtriva promote truvada united states us commercial team sell united states exclusively wholesale channel following regulatory approval february commenced promotion sale truvada european union european commercial team distributors promote sell truvada japan corporate partner japan tobacco exclusive worldwide license patent rights related technology viread emtriva components truvada iocbrega emory university emory respectively emtriva emtricitabine oral formulation nucleoside analogue reverse transcriptase inhibitor dosed day part combination therapy treat hiv infection adults united states europe emtriva also approved part combination therapy treat hiv infection children promote emtriva united states us commercial team sell united states exclusively wholesale channel promote sell emtriva major european countries european commercial team distributors certain latin american countries distributors promote sell emtriva japan corporate partner japan tobacco exclusive worldwide license patent rights related technology emtriva emory ambisome amphotericin b liposome injection proprietary liposomal formulation amphotericin b antifungal agent treat serious invasive fungal infections caused various fungal species corporate partner astellas pharma inc astellas successor fujisawa usa inc promotes sells ambisome united states promote sell ambisome major countries europe european commercial team hepsera adefovir dipivoxil oral formulation nucleotide analogue hepatitis b virus hbv dna polymerase inhibitor dosed day treat chronic hepatitis b hepsera approved sale united states treatment chronic hepatitis b adults evidence active viral replication either evidence persistent elevations serum aminotransferases alt ast histologically active liver disease us commercial team promotes hepsera united states sell united states exclusively wholesale channel promote sell hepsera major european union countries european commercial team distributors licensed rights commercialize hepsera solely treatment hepatitis b asia latin america certain territories glaxosmithkline inc gsk began selling hepsera japan republic korea taiwan china exclusive worldwide license patent rights related technology hepsera iocbrega vistide cidofovir injection antiviral medication treatment cytomegalovirus cmv retinitis patients acquired immunodeficiency syndrome aids vistide approved sale united states promote vistide united states us commercial team sell united states exclusively wholesale channel countries outside united states vistide sold pfizer inc pfizer successor pharmacia corporation daunoxome liposomal daunorubicin injection liposomal formulation anticancer agent daunorubicin approved sale united states europe certain countries treatment aidsrelated kaposis sarcoma gilead sells product limited number countries currently evaluating supply sales strategy regard product table contents following table lists aggregate product sales major products thousands product product product sales sales sales hiv products viread truvada emtriva total hiv products ambisome hepsera vistide daunoxome total product sales see item note consolidated financial statements pages included annual report product sales geographic area royalties products tamiflu oseltamivir phosphate oral antiviral available capsule form treatment prevention influenza b tamiflu class prescription drugs called neuraminidase inhibitors tamiflu approved treatment influenza children adults countries including united states japan countries european union approved prevention influenza children adults united states japan countries european union developed tamiflu f hoffmannla roche ltd roche roche exclusive right manufacture third parties sell tamiflu worldwide subject obligation pay us percentage net revenues roche generates tamiflu sales macugen pegaptanib sodium injection antiangiogenic injection treatment neovascular agerelated macular degeneration macugen approved us food drug administration fda united states december sales commenced january february product received marketing approval sale european union macugen developed eyetech pharmaceuticals inc eyetech using technology licensed us promoted united states osi pharmaceuticals inc osi successor eyetech pfizer osi holds exclusive rights manufacture sell macugen worldwide subject osis obligation pay us percentage net revenues osi generates macugen sales commercialization distribution us international commercial sales operations marketing subsidiaries australia canada france germany greece ireland italy new zealand portugal spain united kingdom united states commercial teams promote hiv hbv products viread truvada emtriva hepsera direct field contact physicians hospitals clinics healthcare providers involved treatment patients hiv hiv products chronic hepatitis b hepsera sell hiv products hepsera united states exclusively wholesale channel corporate partner astellas promotes sells ambisome us united states sell hiv products hepsera ambisome major european countries european commercial team distributors table contents promote sell distribute products countries outside united states europe including countries asia latin america middle east africa certain territories enter agreements third party distributors granting exclusive right sell products particular territory specified period time agreements provide collaborative efforts distributor us obtaining regulatory approval product specified territory agreements generally grant distributor right market product territory generally establish price distributor must pay product require us deliver quantities product ordered distributor competition products development programs target number diseases conditions including viral fungal infections many commercially available products diseases large number companies institutions spending considerable amounts money resources develop additional products treat diseases current products compete available products based primarily efficacy safety tolerability acceptance doctors patient compliance patent protection ease use price insurance reimbursement coverage distribution marketing adaptability various modes dosing hiv products hiv landscape becoming competitive complex treatment trends continue evolve growing number antihiv drugs currently sold advanced stages clinical development approximately branded drugs available united states hiv products primarily compete fixeddose combination products nucleotidenucleoside reverse transcriptase inhibitors nrti class including combivir azt tc epzicom tc abc trizivir azttcabc sold gsk companies hiv products competing nrti class include bristolmyers squibb company bms roche although hiv products also compete broadly hiv products boehringer ingelheim merck co inc merck abbott laboratories bmss videx ec didanosine became first generic hiv product united states gsks retrovir azt also faces generic competition united states result launch generic azt little impact generic didanosine generic azt price gileads hiv products price decreases hiv products may result ambisome ambisome faces strong competition several current expected competitors competition current expected competitors may erode revenues receive sales ambisome ambisome primarily competes vfend voriconazole developed pfizer caspofungin product developed merck marketed cancidas united states caspofungin elsewhere ambisome also competes lipidbased amphotericin b products including abelcet amphotericin b lipid complex injection sold enzon pharmaceuticals inc united states canada japan table contents medeus pharma ltd europe amphotec amphotericin b cholesteryl sulfate complex injection sold three rivers pharmaceuticals llc worldwide bms numerous generic manufacturers sell conventional amphotericin b also competes ambisome presently unapproved expected competitors class treatments called echinocandins including astellas micafungin received marketing approval japan october review regulatory approval united states canada anidulafungin pfizer formerly vicuron inc product candidate evaluated multiple latestage clinical trials finally schering plough developing noxafil posaconazole currently phase trials recently received positive opinion european regulators aware reports least three lipid formulations claim similarity ambisome becoming available outside united states including anticipated entry one formulation greece impact formulations sales ambisome unknown although formulations may compete markets ambisome hepsera hepsera faces significant competition existing expected therapies treating patients infected hbv hepsera competes primarily antiviral products baraclude entecavir oral nucleoside analogue developed bms launched united states epivir hbv lamivudine developed gsk collaboration shire pharmaceuticals shire sold major countries throughout north south america europe asia hepsera may also face competition clinicalstage candidates including telbivudine oral nucleoside analogue developed novartis pharmaceuticals corporation novartis idenix pharmaceuticals limited idenix currently review approval united states europe pradefovir mesylate oral antiviral compound developed valeant pharmaceuticals international currently phase trials hepsera also competes established immunomodulatory therapies including introna interferon alfab sold schering plough major countries throughout north south america europe asia pegasys pegylated interferon alfaa injectable drug similar introna sold roche treatment hbv vistide vistide competes number drugs also treat cmv retinitis including cytovene iv cytovene ganciclovir sold intravenous oral formulations roche ocular implant bausch lomb incorporated valcyte valganciclovir also marketed roche foscavir foscarnet intravenous drug sold astrazeneca vitravene fomivirsen drug injected directly eye sold cibavision tamiflu tamiflu competes relenza zanamivir antiinfluenza drug sold gsk relenza neuraminidase inhibitor delivered orallyinhaled dry powder generic competitors include amantadine rimantadine oral tablets inhibit replication influenza virus biocryst pharmaceuticals inc developing injectable formulations peramivir influenza neuraminidase inhibitor treatment influenza currently preclinical trials macugen macugen competes primarily visudyne verteporfin injection sold novartis pharmaceuticals corporation used connection photodynamic therapy genentech inc developing lucentis ranibizumab currently phase trials pending fda approval approved compete directly macugen number companies pursuing development technologies competitive research programs competing companies include specialized pharmaceutical firms large pharmaceutical companies acting either independently together biopharmaceutical companies furthermore academic institutions government agencies public private organizations conducting research may seek patent protection may establish collaborative arrangements competitive products programs table contents anticipate face increased competition future competitors introduce new products market new technologies become available determine existing products new products competitors develop effective effectively marketed sold develop competitive products could render technology products obsolete noncompetitive recover money resources used develop products collaborative relationships part business strategy establish collaborations companies universities medical research institutions assist clinical development andor commercialization certain products product candidates provide support research programs also evaluate opportunities acquiring products rights products technologies complementary business companies universities medical research institutions information regarding relationships including financial accounting impact business found item note consolidated financial statements pages included annual report commercial collaborations following list representative commercial collaborations year collaboration partner program area signing roche tamiflu emory emtricitabine iocbrega viread truvada hepsera vistide japan tobacco viread truvada emtriva gsk hepsera pfizer macugen vistide osi liposome products macugen sumitomo ambisome md anderson cancer center hepsera astellas ambisome ulehi selex f hoffmannla roche ltd together hoffmannla roche inc roche september entered development license agreement roche develop commercialize therapies treat prevent viral influenza tamiflu antiviral oral formulation treatment prevention influenza codeveloped us roche original agreement roche exclusive right manufacture sell tamiflu worldwide subject obligation pay us percentage net sales roche generated tamiflu sales june delivered notice termination roche material breach original agreement november resolved dispute roche agreed terminate related arbitration proceeding pending parties connection dispute resolution entered first amendment supplement original agreement roche amendment eliminates cost goods adjustments royalty calculation retroactive calendar year future calculations amendment also provides formation joint manufacturing committee review roches existing manufacturing capacity tamiflu global plans manufacturing tamiflu us commercial committee evaluate commercial plans strategies tamiflu united states joint supervisory committee evaluate roches overall commercial plans tamiflu global basis committees consists representatives gilead roche amendment also option provide specialized sales force supplement roches us marketing efforts tamiflu table contents emory university emory april triangle pharmaceuticals inc triangle obtained january acquired part acquisition triangle exclusive worldwide license emorys rights purified forms emtricitabine use hiv hbv indications prior july paid royalties emory respect worldwide net sales product containing emtricitabine july royalty pharma purchased respectively royalty interest owned emory exchange elimination emtricitabine royalties payable emory since july paid royalties respect worldwide net sales products containing emtricitabine directly royalty pharma rate proportional share purchase price also july made payment emory connection amendment restatement existing license agreement emory pertained obligation develop emtricitabine hepatitis b indication institute organic chemistry biochemistry academy sciences czech republic rega stichting iocbrega entered agreements iocbrega relating certain nucleotide compounds discovered two institutions agreements received exclusive right manufacture use sell nucleotide compounds obligated pay iocbrega percentage net revenues received sales products containing compounds subject minimum royalty payments products covered original agreement included vistide hepsera viread december agreements iocbrega amended provide reduced royalty rate future sales product incorporating adefovir active ingredient hepsera tenofovir active ingredient viread truvada return upfront payment us upon signing amendment august agreements iocbrega amended include truvada future fixeddose combination products contain licensed technology iocbrega agreed waive right royalty sales viread truvada developing countries sell products cost gilead access program japan tobacco inc japan tobacco july entered licensing agreement japan tobacco japan tobacco would commercialize hiv product portfolio specifically viread truvada emtriva japan terms agreement received upfront license fee entitled receive additional cash payments upon achievement certain milestones japan tobacco also required pay us royalty net sales products japan march viread approved sale japan march emtriva truvada approved sale japan glaxosmithkline inc gsk april entered licensing agreement gsk providing gsk right commercialize hepsera asia latin america certain territories agreement retained rights hepsera united states canada eastern western europe australia new zealand turkey gsk received exclusive rights develop hepsera solely treatment chronic hepatitis b territories significant include china japan republic korea taiwan received upfront license fee certain milestone payments entitled receive additional payments upon achievement certain milestones gsk full responsibility development commercialization hepsera territories addition gsk required pay us royalties net product sales hepsera gsks hepatitis product epivirhbvzeffix gsk territories hepsera launched japan republic korea taiwan china pfizer inc pfizer december osi successor eyetech granted pfizer sublicense relating macugen connection sublicense entered license pfizer terms contained agreement osi december entered agreement osi fill finish macugen osi three years macugen approved fda united states december sales commenced january february product received marketing approval sale european union table contents entered agreement pfizer successor pharmacia corporation relating vistide agreement pfizer exclusive right market sell vistide countries outside united states subject payment us percentage net product sales required sell pfizer bulk cidofovir maintain vistide patents connection agreement received upfront license fee cash payment upon obtaining marketing approval europe well certain royalties net sales vistide osi pharmaceuticals inc osi december completed sale oncology assets osi terms agreement entitled additional payments osi either cash combination cash osi stock osi reaches certain development milestones nx advanced oncology product candidates sold osi related manufacturing agreement produce nx gs l two liposomal drug candidates included sale march entered agreement osi successor eyetech relating macugen terms agreement osi worldwide rights therapeutic uses macugen responsible research development costs entitled cash payments osi osi reaches certain milestones well royalties worldwide net sales macugen december entered agreement osi fill finish macugen osi three years dainippon sumitomo pharma co ltd sumitomo september entered agreement sumitomo pursuant sumitomo agreed develop market ambisome japan terms agreement received upfront license fee addition entitled receive additional payments certain clinical commercial milestones met well receive royalties ambisome sales japan md anderson cancer center entered agreement md anderson cancer center relating hepsera connection agreement paid upfront license fee required pay md anderson cancer center percentage net sales based upon sales hepsera astellas pharma inc astellas entered agreement astellas successor fujisawa usa inc related rights market ambisome agreement amended astellas responsible promotion ambisome united states astellas sole marketing rights ambisome canada exclusive marketing rights ambisome rest world provided pay royalties astellas connection sales significant markets asia including china india japan korea taiwan astellas collects payments sale ambisome united states canada entitled receive royalties based specified percentage astellas gross profits sale ambisome united states canada university license equity holdings inc ulehi ongoing collaborative arrangement ulehi successor university technology corporation predecessor university research corporation technology holding company university colorado boulder relating identification aptamers oligonucleotides diagnostic therapeutic applications using selex technology arrangement ulehi granted us present future rights inventions covered patents patent applications selex technology improvements selex technology makes discovers oligonucleotides molecules makes using selex technology computer software related selex technology required pay ulehi royalties based revenues generated sales products derived using selex technology including revenues based license agreement osi relating macugen may ulehi assigned part royalty income capital royalty partners lp pursuant consent agreement signed connection assignment pay part royalty obligation related selex process patent capital royalty partners lp table contents developing world collaborations following list representative developing world collaborations aspen pharmacare october entered nonexclusive manufacture distribution agreement aspen pharmacare providing manufacture distribution viread truvada certain developing world countries included gilead access program gilead access program december established gilead access program pursuant agreed sell viread cost developing countries africa caribbean latin america southeast asia expanded access program august include truvada august announced significant price reduction viread truvada made available gilead access program take steps ensure viread truvada sold program used serve patients developing world diverted markets institute one world health january entered agreement institute one world health pursuant provide ambisome cost phase clinical trial evaluating ambisome treatment visceral leishmaniasis paromomycin india greatest global burden visceral leishmaniasis clinical trial conducted institute one world health partnership world health organization dart study november entered collaborative agreement medical research council mrc united kingdom boehringer ingelheim gmbh gsk connection fiveyear clinical study conducted mrc antiretroviral hiv therapy africa trial called dart study development antiretroviral therapy aimed studying clinical versus laboratory monitoring practices structured treatment interruptions continuous antiretroviral therapy adults hiv infection subsaharan africa provide viread cost dart study bill melinda gates foundation family health international october entered agreement bill melinda gates foundation family health international fhi provide viread fhis multinational clinical trial evaluating vireads effectiveness method reducing risk hiv infection among sexually active adults regularly exposed hiv clinical trials conducted fhi funded million grant gates foundation research collaborations following list representative research collaborations collaboration partner program area year signing japan tobacco gs also known jtk treatment hiv bms truvadasustiva fixeddose regimen treatment hiv achillion gs also known ach treatment hepatitis c hcv genelabs nucleoside rna polymerase inhibitors treatment hcv chiron small molecule therapeutics certain hcv drug targets japan tobacco march entered licensing agreement japan tobacco japan tobacco granted gilead exclusive rights develop commercialize novel hiv integrase inhibitor gs also known jtk countries world excluding japan table contents japan tobacco would retain rights terms agreement paid upfront license fee additionally obligated make additional cash payments upon achievement certain milestones well pay royalties based future net product sales territories may market drug bristolmyers squibb company bms december entered collaboration bms develop commercialize fixeddose regimen truvada bmss sustiva efavirenz united states bms structured collaboration joint venture forming limited liability company called bristolmyers squibb gilead sciences llc terms collaboration bms granted royaltyfree licenses joint venture use respective companyowned technologies return granted license joint venture use intellectual property results collaboration ownership interests joint venture us bms reflect respective economic interests based fraction estimated net selling price fixeddose regimen product attributable truvada sustiva respectively adjusted annual basis since net selling price truvada may change time relative net selling price sustiva bmss respective economic interests joint venture may vary annually primary responsibility clinical development activities regulatory filings relating new products resulting collaboration bms share marketing sales efforts parties provide equivalent sales force efforts minimum number years daily operations joint venture governed four primary joint committees responsible accounting financial reporting product distribution joint venture january gilead bms announced obtained data supporting bioequivalence new formulation fixeddose combination product gilead bms anticipate filing new drug application nda fda second quarter achillion pharmaceuticals inc achillion november entered exclusive license collaboration agreement achillion pursuant agreement granted worldwide rights research development commercialization certain small molecule hcv replication inhibitors involving hcv protease treatment hepatitis c collaboration achillion obligated continue development compounds according mutually agreed upon development plan completion proofofconcept clinical study hcvinfected patients costs incurred achieve proofofconcept shared equally gilead achillion contractually agreed upon budget following proofofconcept study obligated assume full responsibilities incur costs associated development commercialization compounds warranting development achillion option participate us commercialization efforts future products arising collaboration conjunction signing collaboration paid upfront license fee made equity investment achillions convertible preferred stock also agreed make payments achillion upon achievement certain milestones outlined agreement pay royalties future net sales products arising collaboration achillion began dosing healthy volunteers phase clinical study gs also known ach treatment hepatitis c genelabs technologies inc genelabs september entered license research collaboration agreement genelabs research develop commercialize certain genelabs novel nucleoside inhibitors hcv polymerase treatment chronic infection caused hcv conjunction signing agreement paid upfront license fee initial term three years term may extended additional year gileads option genelabs obligated lead research efforts agreed provide annual funding fulltime equivalents lead development commercialization activities obligated make additional payments upon achievement certain milestones pay royalties future net sales selected compounds developed approved relation collaboration table contents chiron corporation chiron august entered nonexclusive licensing agreement chiron research development commercialization small molecule therapeutics selected hcv drug targets agreement received nonexclusive rights use chirons hcv technology develop commercialize products treatment hcv terms agreement paid chiron upfront license fee agreed make additional payments certain clinical regulatory contractually determined milestones met additionally obligated make royalty payments event product developed using licensed technology research development addition entering collaborations companies universities medical research institutions seek add existing portfolio products internal discovery clinical development programs active inlicensing product acquisition strategy acquisition triangle completed january research scientists foster city san dimas california durham north carolina engaged discovery development new molecules technologies hope lead new medicines novel formulations existing drugs therapeutic focus area life threatening infectious diseases internal research focused discovery development treatments viral infections particularly hiv hbv hcv hiv filed investigational new drug ind application december gs one internal integrase clinical candidates initiated phase clinical study healthy volunteers february january also announced completed phase study gs novel hiv integrase inhibitor licensed japan tobacco based results study gilead anticipates initiating phase clinical trial second quarter hepatitis b progressing enrollment two phase studies comparing efficacy safety tenofovir df active pharmaceutical ingredient viread versus hepsera patients hepatitis b anticipate completing enrollment second half addition using technology licensed chiron several inhouse programs designed discover small molecule inhibitors hcv rna polymerase hcv protease believe small molecule therapeutics treatment hepatitis c could one day lead better treatment outcomes patients programs require extensive investments take many years total research development expenses million compared million million patents proprietary rights patents proprietary rights important business properly designed enforceable patent difficult competitors use technology create competitive products difficult competitors obtain patent prevents us using technology create part business strategy actively seek patent protection united states internationally file additional patent applications appropriate cover improvements compounds products technology also rely trade secrets internal knowhow technological innovations agreements third parties develop maintain protect competitive position ability competitive depend success strategy number us foreign patents patent applications rights patents related compounds products technology certain issued patents enforceable provide adequate protection pending patent applications result issued patents table contents following table shows actual estimated expiration dates united states europe primary patents patents may issue pending applications cover compounds marketed products us european patent patent products expiration expiration daunoxome vistide hepsera ambisome tamiflu macugen viread emtriva truvada patents covering viread hepsera vistide emtriva truvada held third parties acquired exclusive rights patents agreements parties see commercial collaborations patents cover active ingredients ambisome instead hold patents liposomal formulations compound also protect formulations trade secrets although patent filings covering forms adefovir dipivoxil active ingredient hepsera china certain countries asia applications pending various countries asia including china relate specific forms formulations hepsera asia major market therapies hbv indication hepsera developed may obtain patents certain products many years obtain marketing approval products patents limited life may begin run prior commercial sale related product commercial value patent may limited however may able apply patent term extensions example extensions patents vistide granted united states number european countries compensating part delays obtaining marketing approval similar patent term extensions may available products developing certain obtain also important infringe patents proprietary rights others violate agreements grant proprietary rights us infringe patents violate agreements could prevented developing selling products using processes covered patents agreements could required obtain license third party allowing us use technology certain required could obtain license thirdparty technology could obtain one reasonable cost able obtain required license could adversely affected patent applications confidential least period time patent issues may know competitors filed patent applications technology covered pending applications first invent technology subject patent applications competitors may filed patent applications received patents may obtain additional patents proprietary rights block compete patents competitors file patents applications covering technology may participate interference proceedings litigation determine right patent litigation interference proceedings expensive even ultimately successful patents relating pharmaceutical biopharmaceutical biotechnology products compounds processes cover existing compounds products processes likely file future always provide complete adequate protection future litigation reexamination proceedings regarding enforcement validity existing patents future patents could invalidate patents substantially reduce protection addition pending patent applications patent table contents applications filed collaborative partners may result issuance patents may result patents provide adequate protection result may able prevent third parties developing compounds products developed developing addition certain countries africa asia including china permit enforcement patents manufacturers able sell generic versions products countries part approval process products fda determined products would granted exclusivity period manufacturers applications approval generic versions product granted generic manufacturers often wait challenge patents protecting products granted exclusivity one year prior end exclusivity period time time received notices manufacturers indicating intend import chemical intermediates possibly use making products therefore possible generic manufacturers considering attempts seek fda approval similar identical drug abbreviated new drug application application form typically used manufacturers seeking approval generic drug patents subject challenges may need spend significant resources defend challenges may able defend patents successfully also rely unpatented trade secrets improvements unpatented internal knowhow technological innovation particular great deal liposomal manufacturing expertise key component liposomal technology covered patents instead protected trade secret protect rights mainly confidentiality agreements corporate partners employees consultants vendors agreements provide confidential information developed made known individual course relationship us kept confidential used disclosed third parties except specified circumstances case employees agreements provide inventions made individual employed us exclusive property certain parties comply confidentiality agreements adequate remedies breach trade secrets otherwise become known independently discovered competitors research development agreements inventions discovered certain cases become jointly owned us corporate partner cases become exclusive property one us difficult determine owns particular invention disputes could arise regarding inventions manufacturing raw materials antiviral products commercialscale manufacturing facilities antiviral products contract third parties manufacture antiviral drugs clinical commercial purposes including viread truvada emtriva hepsera vistide tamiflu use four third party contract manufacturers manufacture tenofovir disoproxil fumarate active pharmaceutical ingredient viread emtricitabine active pharmaceutical ingredient emtriva adefovir dipivoxil active pharmaceutical ingredient hepsera cidofovir active pharmaceutical ingredient vistide two third party contract manufacturers manufacturing active pharmaceutical ingredient viread truvada hepsera tableting performed two third party contract manufacturers manufacturing sites qualified approved supply product united states european union markets emtriva capsulation completed two third party contract manufacturers two manufacturers one approved supply product united states european union markets second manufacturer qualified expect submission regulatory approval use single third party manufacturer supply vistide drug product table contents process installing additional filling packaging capabilities facilities san dimas california dublin ireland upon regulatory approval allow us fill package drug product viread truvada emtriva hepsera finished forms roche third parties responsible manufacturing tamiflu agreement roche joint manufacturing committee composed representatives gilead roche opportunity review roches existing manufacturing capacity tamiflu global plans manufacturing tamiflu future antiviral products need develop additional manufacturing capabilities establish additional third party suppliers manufacture sufficient quantities product candidates undertake clinical trials manufacture sufficient quantities product approved commercial sale unable develop manufacturing capabilities internally contract large scale manufacturing third parties acceptable terms future antiviral products ability conduct large scale clinical trials meet customer demand commercial products would adversely affected believe technology use manufacture products compounds proprietary antiviral products disclosed necessary aspects technology contract manufacturers enable manufacture products compounds us agreements manufacturers intended restrict using revealing technology certain manufacturers comply restrictions addition manufacturers could develop technology related work perform us may need manufacture products compounds could required enter agreement manufacturer wanted use technology allow another manufacturer use technology manufacturer could refuse allow us use technology could demand terms use technology acceptable ambisome manufacture ambisome commercial quantities facilities san dimas medicines control agency united kingdom fda approved commercial production ambisome facilities produced import ambisome european union manufacturing facility dublin ireland perform quality control testing final labeling packaging distribution european union elsewhere use commercially available materials equipment manufacture products currently obtain amphotericin b active pharmaceutical ingredient ambisome cholesterol use manufacture ambisome single approved suppliers ambisome sold freezedried product currently freezedry fill ambisome san dimas manufacturing facility also use third party freezedry fill additional product needed given current projections ambisome demand believe sufficient capacity meet future demand also option installing additional freezedrying capacity san dimas additional supply become necessary macugen manufacture macugen commercial quantities fda approved facilities san dimas manufacturing agreement osi use commercially available materials equipment produce fill product currently osi provides syringes raw materials used manufacture macugen including pegaptanib sodium active pharmaceutical ingredient macugen single approved suppliers contracted osi given osis current projections macugen demand believe sufficient capacity meet future demand process installing additional production filling capacity san dimas table contents unsuccessful installation additional production filling capacity san dimas locate appropriate third parties meet need ability meet increased macugen demand would diminished many materials utilize operations made one facility since suppliers key components materials must named nda filed fda product significant delays occur qualification new supplier required delivery material suppliers interrupted reason may unable ship viread ambisome hepsera emtriva truvada vistide supply products development clinical trials seasonal operations backlog worldwide product sales reflect significant degree seasonality however contract royalty revenue represented total revenues affected seasonality example royalty revenue receive roches sale tamiflu impacted severity associated flu seasons planning response avian influenza pandemic threat part operate markets characterized short lead times absence significant backlogs believe backlog information material business whole government regulation operations activities subject extensive regulation numerous government authorities united states countries united states drugs subject rigorous fda regulation federal food drug cosmetic act federal state statutes regulations govern testing manufacture safety effectiveness labeling storage record keeping approval advertising promotion products result regulations product development product approval process expensive time consuming fda must approve drug sold united states general process approval follows preclinical testing test drug candidate humans must study drug laboratory experiments animals generate data support drugs potential safety benefits submit data fda ind application seeking approval test compound humans clinical trials fda accepts ind application study drug human clinical trials determine drug safe effective clinical trials involve three separate phases often overlap take many years expensive three phases subject considerable regulation follows phase drug given small number healthy human subjects patients test safety dose tolerance pharmacokinetics metabolism distribution excretion phase drug given limited patient population determine effect drug treating disease best dose drug possible side effects safety risks drug phase compound appears effective safe phase clinical trials phase clinical trials commenced confirm results phase clinical trials longterm involve significantly larger population conducted numerous sites different geographic regions carefully designed provide reliable conclusive data regarding safety benefits drug uncommon drug appears promising phase clinical trials fail rigorous reliable phase clinical trials table contents fda approval process believe data phase clinical trials show adequate level safety effectiveness file nda fda seeking approval sell drug particular use fda review nda often hold public hearing independent advisory committee expert advisors asks additional questions makes recommendations regarding drug committee makes recommendation fda binding generally followed fda fda agrees compound met required level safety effectiveness particular use allow us sell drug united states use unusual however fda reject application believes drug safe enough effective enough believe data submitted reliable conclusive point process development drug could stopped number reasons including safety concerns lack treatment benefit certain clinical trials currently conducting conduct future completed successfully within specified time period may choose fda may require us delay suspend clinical trials time appears patients exposed unacceptable health risk drug candidate appear sufficient treatment benefit fda may also require phase nonregistrational studies explore scientific questions characterize safety efficacy commercial use drug fda may also require us provide additional data information improve manufacturing processes procedures facilities may require extensive postmarketing testing surveillance monitor safety benefits product candidates determines nda contain adequate evidence safety benefits drug addition even fda approves drug could limit uses drug fda withdraw approvals believe complying regulatory standards problems uncovered occur approval addition obtaining fda approval drug obtain fda approval manufacturing facilities drug sell including companies manufacture drugs us well facilities subject periodic inspections fda fda must also approve foreign establishments manufacture products sold united states facilities subject periodic regulatory inspection manufacturing facilities located california including san dimas facility foster city facility also must licensed state california compliance local regulatory requirements drugs treat serious lifethreatening diseases conditions adequately addressed existing drugs development program designed address unmet medical need may designated fast track products fda may eligible accelerated priority review drugs treatment hiv designated use presidents emergency plan aids relief pepfar may also qualify expedited priority review viread truvada received accelerated approval priority reviews drugs receiving accelerated approval must monitored postmarketing clinical trials order confirm safety benefits drug also subject federal state local regulations regarding workplace safety protection environment use hazardous materials chemicals viruses various radioactive compounds research development activities eliminate risk accidental contamination injury materials misuse accidents involving materials could lead significant litigation fines penalties drugs also subject extensive regulation outside united states european union centralized approval procedure authorizes marketing product countries european union includes major countries europe procedure used approval one country table contents european union used obtain approval another country european union two simplified application processes mutual recognition procedure decentralized procedure rely principle mutual recognition receiving regulatory approval european registration procedures pricing reimbursement approvals also required countries pricing reimbursement successful commercialization depends part availability governmental thirdparty payor reimbursement cost products government authorities thirdparty payors increasingly challenging price medical products services particularly innovative new products therapies business may adversely affected increase global pricing pressures united states number legislative regulatory changes healthcare system could impact pricing products december president bush signed law new medicare prescription drug coverage legislation part legislation authorizes centers medicare medicaid services cms agency within department health human services administers medicare implement new medicare part coverage benefit prescription drugs prescription drug program began january many factors influence possible impact gilead drugs class may covered payment levels new medicare program may lower previous medicare payment medicare patients pay coinsurance may influence products recommended physicians selected patients program enrollment mandatory dually eligible medicaid medicare assurance drugs recognized new medicare part program outpatient prescription drugs paid levels reflect current historical levels federal medicare proposals along state medicaid drug payment changes healthcare reforms could also lower payment products results operations could materially adversely affected reimbursement changes emerging beyond medicare prescription drug coverage legislation extent private insurers blue cross blue shield managed care programs follow medicaid coverage payment developments adverse effects lower medicare payment may magnified private insurers adopting lower payment additionally states enacted health care reform legislation federal state developments possible impact proposed legislation reforms unclear may result pricing reimbursement restrictions could adversely impact revenues europe success viread truvada emtriva hepsera tamiflu depend largely obtaining maintaining government reimbursement many european countries patients use prescription drugs reimbursed governments even reimbursement available reimbursement policies may adversely affect ability sell products profitable basis example europe many international markets governments control prices prescription pharmaceuticals expect prices prescription pharmaceuticals decline life product volumes increase new drugs come market may face significant price decreases products across much europe believe continue foreseeable future governments struggle escalating health care spending result pricing practices may become difficult maintain historic levels profitability achieve expected rates growth testing manufacturing marketing use products well products development involve substantial risk product liability claims maintain product liability insurance however successful product liability claim us may covered insurance could require us pay amounts beyond provided insurance either could impair financial condition ability clinically test market products table contents health care fraud abuse laws subject various federal state laws pertaining health care fraud abuse including antikickback laws false claims laws antikickback laws make illegal prescription drug manufacturer solicit offer receive pay remuneration exchange induce referral business including purchase prescription particular drug due breadth statutory provisions increasing attention given law enforcement authorities possible certain practices may challenged antikickback similar laws false claims laws prohibit anyone knowingly willingly presenting causing presented payment thirdparty payors including medicare medicaid claims reimbursed drugs services false fraudulent claims items services provided claimed claims medically unnecessary items services sales marketing activities may subject scrutiny laws violations fraud abuse laws may punishable criminal andor civil sanctions including fines civil monetary penalties well possibility exclusion federal health care programs including medicare medicaid government allege convict us violating laws could material adverse effect results operations compulsory licenses governments developing countries could require grant compulsory licenses allow competitors manufacture sell versions products thereby reducing product sales certain offices government brazil expressed concern affordability hiv products declared considering issuing compulsory licenses permit manufacture otherwise patented products hiv infection including viread currently engaged discussions brazilian government regarding affordability hiv products addition concerns cost availability tamiflu fear grows potential avian flu pandemic generated international discussions potential compulsory licensing tamiflu patents addition roche may issue voluntary licenses permit third party manufacturing tamiflu example roche granted sublicense shanghai pharmaceutical group co ltd china sublicense indias hetero drugs limited india certain developing countries one compulsory licenses issued permitting generic manufacturing override gileads tamiflu patents roche issue additional voluntary licenses permit thirdparty manufacturing tamiflu developments could reduce royalties received roches sales tamiflu compulsory licenses generic versions products could significantly reduce sales adversely affect results operations particularly generic versions products imported territories existing commercial sales employees january approximately fulltime employees believe good relations employees environment seek comply applicable statutory administrative requirements concerning environmental quality made continue make expenditures environmental compliance protection expenditures compliance environmental laws expected material effect capital expenditures results operations competitive position table contents item risk factors evaluating business carefully consider following risks addition information annual report following risks could materially adversely affect business results operations financial condition note factors investors permitted private securities litigation reform act possible predict identify factors therefore consider risks complete statement potential risks uncertainties face substantially revenues derived sales limited number products unable maintain continue increasing sales hiv products results operations may adversely affected currently dependent sales hiv products especially viread truvada support existing operations hiv products exclusively nucleoside class antiviral therapeutics treatment paradigm hiv change causing nucleosidebased therapeutics fall favor unable continue increasing hiv product sales results operations would likely suffer would likely need scale back operations including spending research development efforts hiv product sales year ended december billion total revenues sales viread truvada comprised respectively total hiv product sales may able continue growth rate sales hiv products reasons stated risk factor section particular following reasons hiv products used longer period time many patients combination products additional studies conducted new issues respect safety resistance interactions drugs may arise could cause us provide additional warnings labels narrow approved indications halt sales product could reduce revenues product matures private insurers government reimbursers often reduce amount reimburse patients products increases pressure us reduce prices large part market hiv products consists patients already taking hiv drugs successful encouraging physicians change patients regimens include hiv products sales hiv products limited generic hiv products introduced major markets ability maintain pricing may affected fail commercialize new products expand indications existing products prospects future revenues stock price may adversely affected introduce new products increase revenues existing products able increase total revenues fail increase sales hiv products may able increase revenues expand research development efforts may face difficulties collaboration efforts bms commercialize onceaday single pill combination truvada sustiva example regulatory approval nda expect file fda second quarter may granted timely basis face significant competition face significant competition businesses substantially greater resources addition competitors products operated fields compete longer hiv products compete primarily products gsk markets fixeddose combination products compete truvada ambisome encountering significant competition new products produced merck pfizer addition aware reports least three lipid table contents formulations claim similarity ambisome becoming available outside united states including anticipated entry one formulation greece hepsera encountered increased competition launch bmss baraclude entecavir potential future competition telbivudine developed novartis idenix awaiting approval united states europe companies may significantly impede ability successful antiviral products ambisome significant safety issues arise marketed products sales may decline would adversely affect results operations data support marketing approvals products form basis safety warnings product labels obtained controlled clinical trials limited duration cases limited postapproval use safety efficacy studies viread emtriva dosed separate products ongoing underway longer period time safety efficacy studies truvada viread emtriva together also underway following approval products used longer periods time many patients taking numerous medicines many underlying health problems would monitored dosing compliance drugs used longer periods time patients found expect continue find new issues safety resistance drug interaction issues may require us provide additional warnings labels narrow approved indications could reduce market acceptance products serious safety resistance interaction issues arise marketed products sales products could limited halted us regulatory authorities operations depend compliance complex fda comparable international regulations failure obtain broad approvals timely basis achieve continued compliance could delay halt commercialization products products develop must approved marketing sale regulatory authorities approved subject extensive regulation fda comparable regulatory agencies countries continuing clinical trials viread truvada emtriva ambisome hepsera currently approved additional uses anticipate file marketing approval additional countries additional products next several years products may fail receive marketing approval timely basis addition marketed products manufacture sell products subject extensive continued regulation review discovery previously unknown problems marketed products problems manufacturing promotional activities may result restrictions products including withdrawal products market fail comply applicable regulatory requirements could subject penalties including fines suspensions regulatory approvals product recalls seizure products criminal prosecution depend contract research organizations results clinical trials uncertain may support continued development product pipeline would adversely affect prospects future revenue growth gilead extensively outsources clinical trial activities usually performs small portion startup activities inhouse rely third party contract research organizations cros perform clinical studies including document preparation site identification screening preparation pre study visits training program management dispute disruption relationship cros clinical trials may delayed addition required demonstrate safety effectiveness products develop intended use extensive preclinical studies clinical trials results preclinical early clinical studies always accurately predict results later largescale clinical trials even successfully completed largescale clinical trials may result marketable products table contents products development fails achieve primary endpoint clinical trials safety issues arise commercialization drug candidate could delayed halted addition clinical trials involving commercial products could raise new safety issues existing products could turn reduce revenues manufacturing problems could delay product shipments regulatory approvals may adversely affect results operations depend third parties perform manufacturing activities effectively timely basis third parties fail perform required could impair ability deliver products timely basis cause delays clinical trials applications regulatory approval events could harm competitive position manufacturing process pharmaceutical products highly regulated regulators may shut manufacturing facilities believe comply regulations manufacturers subject fdas current good manufacturing practices extensive regulations governing manufacturing processes stability testing recordkeeping quality standards similar regulations effect countries addition manufacturing operations subject routine inspections regulatory agencies depend third party manufacturers manufacture viread truvada emtriva hepsera vistide including truvada viread made available physicians treatment programs cost developing countries access program rely third parties manufacture active pharmaceutical ingredient final drug product clinical commercial purposes addition roche either third parties responsible manufacturing tamiflu thirdparty manufacturers may develop problems control problems may adversely affect business manufacture ambisome macugen facilities san dimas california formulation manufacturing facilities united states manufacturing facility ireland conducts quality control testing labeling packaging addition use third parties alternate contract suppliers fill freeze dry certain batches product event natural disaster including earthquake equipment failure strike difficulty may unable replace manufacturing capacity timely manner would unable manufacture ambisome macugen meet market needs may able obtain materials necessary manufacture products could limit ability generate revenues many materials utilize operations made one facility example depend single suppliers high quality amphotericin b distearoylphosphatidylcholine high quality cholesterol used manufacture ambisome suppliers key components materials must named nda filed fda product significant delays occur qualification new supplier required delivery material suppliers interrupted reason may unable ship viread ambisome hepsera emtriva truvada vistide supply products development clinical trials depend relationships companies sales marketing performance revenues failure maintain relationships poor performance companies disputes companies could negatively impact business rely number significant collaborative relationships major pharmaceutical companies sales marketing performance include collaborations astellas sumitomo ambisome gsk hepsera roche tamiflu pfizer vistide osi pfizer macugen japan tobacco viread truvada emtriva joint venture bms develop commercialize fixeddose regimen truvada sustiva many countries rely international distributors sales viread table contents truvada emtriva ambisome hepsera outside united states relationships also involve clinical development products partners reliance collaborative relationships poses number risks including able control whether corporate partners devote sufficient resources programs products disputes may arise future respect ownership rights technology developed corporate partners disagreements corporate partners could lead delays termination research development commercialization product candidates result litigation arbitration contracts corporate partners may fail provide significant protection may fail effectively enforced one partners fails perform corporate partners considerable discretion electing whether pursue development additional products may pursue alternative technologies products either collaboration competitors corporate partners marketing rights may choose devote fewer resources marketing products products development distributors corporate partners may unable pay us given risks great deal uncertainty regarding success current future collaborative efforts efforts fail product development commercialization new products could delayed revenue existing products could decline april licensing agreement gsk gave gsk right control clinical regulatory development commercialization hepsera territories asia africa latin america include major markets hepsera china japan taiwan republic korea success hepsera territories depend almost entirely efforts gsk regard gsk promotes epivirhbvzeffix product competes hepsera consequently gsks marketing strategy hepsera may influenced promotion epivirhbv receive royalties gsk equal percentage gsks net sales hepsera well net sales gsks epivirhbvzeffix gsk fails devote sufficient resources succeed developing commercializing hepsera territories potential revenues sales hepsera may substantially reduced expenses associated clinical trials sales fluctuations result inventory levels held wholesalers may cause earnings fluctuate could adversely affect stock price clinical trials required regulatory approval products well clinical trials required conduct approval extremely expensive difficult accurately predict control amount timing expenses quarter quarter uneven unexpected spending programs may cause operating results fluctuate quarter quarter addition year ended december approximately product sales united states three wholesalers amerisourcebergen corp cardinal health inc mckesson corp inventory levels held wholesalers cause operating results fluctuate unexpectedly sales wholesalers match end user demand us wholesalers entered inventory management agreements may completely effective matching inventory levels end user demand make estimates determine end user demand approximately half product sales occurs outside united states currency fluctuations may cause earnings fluctuate could adversely affect stock price significant percentage product sales denominated foreign currencies primarily euro increases value us dollar foreign currencies past reduced future may table contents reduce us dollar equivalent sales negatively impact financial condition results operations use foreign currency forward contracts hedge percentage forecasted international sales primarily denominated euro currency also hedge portion accounts receivable balances denominated foreign currencies reduces eliminate exposure currency fluctuations date sale recorded date cash collected hedging program hedges portion total exposure significant foreign exchange rate fluctuations within short period time could still adversely affect results operations face credit risks european customers may adversely affect results operations european product sales government owned supported customers greece italy portugal spain subject significant payment delays due government funding reimbursement practices accounts receivable government owned supported customers countries totaled million december historically receivables tended accumulate period time settled large lump sum payments government funding became available significant changes occur reimbursement practices european governments government funding becomes unavailable may able collect amounts due us customers results operations would adversely affected plan supply viread truvada certain developing countries access program may expose us unforeseen liabilities risks launched access program pursuant supply viread truvada cost developing countries supply distribution drugs resourcepoor environment complicated undertaking program develops could face unforeseen challenges risks could give rise unforeseen liabilities example patients less developed countries using viread truvada may closely supervised doctor would developed nations accordingly may increased likelihood viread truvadarelated complications going undetected untreated could result significant liability gilead product revenues could reduced imports countries products available lower prices prices products based local market economics competition sometimes differ country country sales countries relatively higher prices may reduced products imported countries lower price markets cases pharmaceutical products sold steeply discounted prices developing world reexported european countries could resold much higher prices happens products particularly viread truvada agreed provide cost access program revenues would adversely affected addition european union required permit cross border sales allows buyers countries governmentapproved prices products relatively high purchase products legally countries must sold lower prices additionally us consumers able purchase products including hiv products internet pharmacies countries substantial discounts cross border sales could adversely affect revenues countries may required grant compulsory licenses products face generic competition products number developing countries government officials groups suggested pharmaceutical companies make drugs hiv infection available low cost alternatively governments countries could require grant compulsory licenses allow competitors table contents manufacture sell versions products thereby reducing product sales certain offices government brazil expressed concern affordability hiv products declared considering issuing compulsory licenses permit manufacture otherwise patented products hiv infection including viread currently engaged discussions brazilian government regarding affordability hiv products addition concerns cost availability tamiflu fear grows potential avian flu pandemic generated international discussions potential compulsory licensing tamiflu patents furthermore roche may issue voluntary licenses permit third party manufacturing tamiflu example roche granted sublicense shanghai pharmaceutical group co ltd china sublicense indias hetero drugs limited india certain developing countries one compulsory licenses issued permitting generic manufacturing override gileads tamiflu patents roche issue additional voluntary licenses permit third party manufacturing tamiflu developments could reduce royalties received roches sales tamiflu certain countries permit enforcement patents manufacturers able sell generic versions products countries compulsory licenses sales generic versions products could significantly reduce sales adversely affect results operations particularly generic versions products imported territories existing commercial sales existing products subject reimbursement government agencies third parties pharmaceutical pricing reimbursement pressures may reduce profitability successful commercialization products depends part availability governmental third party payor reimbursement cost products related treatments government health administration authorities private health insurers organizations generally provide reimbursement government authorities thirdparty payors increasingly challenging price medical products services particularly innovative new products therapies resulted lower average sales prices example majority sales ambisome vistide majority sales truvada viread hepsera subject reimbursement government agencies resulting significant discounts list price rebate obligations business may adversely affected increase us international pricing pressures pressures arise rules practices managed care groups judicial decisions governmental laws regulations related medicare medicaid health care reform pharmaceutical reimbursement policies pricing general europe success viread truvada emtriva hepsera ambisome tamiflu also depend largely obtaining maintaining government reimbursement many european countries including united kingdom france patients use prescription drugs reimbursed governments addition negotiating prices governmental authorities delay commercialization twelve months also expect success products development particularly europe depend ability obtain reimbursement even reimbursement available reimbursement policies may adversely affect ability sell products profitable basis example europe many international markets governments control prices prescription pharmaceuticals expect prices prescription pharmaceuticals decline life product volumes increase new drugs come market may face significant price decreases products across much europe believe continue foreseeable future governments struggle escalating health care spending result pricing practices may become difficult maintain historic levels profitability achieve expected rates growth results operations could adversely affected future health care reforms united states foreign jurisdictions number legislative regulatory changes healthcare system could impact pricing products united states december president bush signed law new medicare prescription drug coverage legislation part legislation authorizes centers medicare medicaid services cms agency within department health human services administers medicare implement new medicare part coverage benefit table contents prescription drugs prescription drug program began january many factors influence possible impact gilead drugs class may covered payment levels new medicare program may lower previous medicare payment medicare patients pay co insurance may influence products recommended physicians selected patients program enrollment mandatory dually eligible medicaid medicare assurance drugs recognized new medicare part program outpatient prescription drugs paid levels reflect current historical levels federal medicare proposals along state medicaid drug payment changes healthcare reforms could also lower payment products results operations could materially adversely affected reimbursement changes emerging beyond medicare prescription drug coverage legislation extent private insurers blue cross blue shield managed care programs follow medicaid coverage payment developments adverse effects lower medicare payment may magnified private insurers adopting lower payment additionally states enacted health care reform legislation federal state developments possible impact proposed legislation reforms unclear may result pricing reimbursement restrictions could adversely impact revenues may able obtain effective patents protect technologies use competitors patents companies could require us stop using pay use required technology success depend significant degree ability obtain patents licenses patent rights preserve trade secrets operate without infringing proprietary rights others number us foreign patents patent applications rights patents related compounds products technology risk however issued patents enforceable provide adequate protection pending patent applications result issued patents patent applications confidential least period time patent issues result may know competitors filed patent applications technology covered pending applications first invent technology subject patent applications competitors may filed patent applications received patents may obtain additional patents proprietary rights block compete patents patents cover active ingredients ambisome addition patent filings china certain asian countries covering forms adefovir dipivoxil active ingredient hepsera asia major market therapies hbv indication hepsera developed may obtain patents certain products many years marketing approval obtained products patents limited life may begin run prior commercial sale related product commercial value patent may limited however may able apply patent term extensions addition certain countries africa asia including china permit enforcement patents manufacturers able sell generic versions products countries competitors may file patent applications covering technology may participate interference proceedings litigation determine right patent litigation interference proceedings expensive even ultimately successful part approval process products fda determined products would granted exclusivity period manufacturers applications approval generic versions product granted generic manufacturers often wait challenge patents protecting products granted exclusivity one year prior end exclusivity period time time received notices manufacturers indicating intend import chemical intermediates possibly table contents use making products therefore possible generic manufacturers considering attempts seek fda approval similar identical drug abbreviated new drug application application form typically used manufacturers seeking approval generic drug patents subject challenges may need spend significant resources defend challenges may able defend patents successfully success depends large part ability operate without infringing upon patents proprietary rights third parties infringe patents others may prevented commercializing products may required obtain licenses third parties may able obtain alternative technologies required license reasonable terms fail obtain licenses alternative technologies may unable develop commercialize products addition use significant proprietary technology rely unpatented trade secrets proprietary knowhow protect certain aspects production technologies trade secrets may become known independently discovered competitors may face significant liability resulting products may covered insurance successful claims could materially reduce earnings testing manufacturing marketing use commercial products well products development involve substantial risk product liability claims claims may made directly consumers healthcare providers pharmaceutical companies others although maintain product liability insurance successful product liability claim us may covered insurance could require us pay amounts beyond provided insurance either could impair financial condition ability clinically test market products expensive litigation may reduce earnings named defendant lawsuits regarding use average wholesale price reimbursement rates medicaid also named defendant lawsuit alleging violations federal securities laws adverse results lawsuits could result material damages could significantly reduce earnings cash flows changes effective income tax rate could reduce earnings various factors may favorable unfavorable effects effective income tax rate factors include limited interpretations existing tax laws adoption statement financial accounting standards revised sharebased payment sfas r relating accounting stock options sharebased payments changes tax laws rates future levels research development spending changes accounting standards future levels capital expenditures changes mix earnings various tax jurisdictions operate changes overall levels pretax earnings impact income tax provision resulting abovementioned factors may significant could negative impact results operations recently adopted changes accounting stock options significantly reduce earnings financial accounting standards board fasb recently issued sfas r required record additional compensation expense related stock options equity incentives beyond impact earnings resulting new standard significant negative impact reported results operations compared results reported prior accounting standards stock options sharebased payments item b unresolved staff comments applicable table contents item properties primary facilities located foster city california house executive offices administrative research development activities location buildings lease buildings lease facilities san dimas california house manufacturing warehousing research development activities addition also lease facilities durham north carolina house administrative research development activities outside united states lease facilities cambridge area united kingdom house administrative sales marketing activities commercial medical administrative groups previously based paris france relocated leased facilities london area united kingdom also lease facilities dublin area ireland house manufacturing distribution facilities partly partly lease space addition leased facilities house sales marketing activities france spain portugal italy greece australia germany canada believe existing properties including owned leased sites good condition suitable conduct business believe capital resources sufficient purchase lease construct additional facilities required meet longterm growth needs item legal proceedings information pertaining legal proceedings found item note consolidated financial statements pages annual report incorporated reference herein item submission matters vote security holders applicable table contents part ii item market registrants common equity related stockholder matters issuer purchases equity securities common stock traded nasdaq stock market symbol gild following table sets forth periods indicated high low intraday sale prices per share common stock nasdaq stock market prices represent quotations among dealers without adjustments retail markups markdowns commissions may represent prices actual transactions high low first quarter second quarter third quarter fourth quarter first quarter second quarter third quarter fourth quarter september implemented twoforone stock split form stock dividend share per share amounts periods presented restated reflect stock split february shares common stock outstanding held approximately stockholders record paid cash dividends common stock since inception currently expect retain earnings use operation expansion business therefore anticipate paying cash dividends near future table contents item selected financial data gilead sciences inc selected consolidated financial data thousands except per share data year ended december consolidated statement operations data total revenues purchased inprocess research development note total costs expenses income loss operations gain sale oncology assets note gain warrant note loss marketable securities note provision benefit income taxes note income loss cumulative effect change accounting principle cumulative effect change accounting principle note net income loss amounts per common sharebasic income loss cumulative effect change accounting principle note cumulative effect change accounting principle note net income loss per sharebasic note shares used per share calculationbasic note amounts per common sharediluted income loss cumulative effect change accounting principle note cumulative effect change accounting principle note net income loss per sharediluted note shares used per share calculationdiluted note table contents gilead sciences inc selected consolidated financial datacontinued december consolidated balance sheet data cash cash equivalents marketable securities working capital total assets longterm debt longterm obligations convertible debt retained earnings accumulated deficit total stockholders equity note note gilead recognized million royalty revenue relating resolution dispute roche gilead also recorded tax provision benefit million related repatriation qualified foreign earnings american jobs creation act gilead recorded gain million related warrant purchase capital stock eyetech predecessor osi completed initial public offering gilead completed acquisition net assets triangle aggregate purchase price million approximately million purchase price allocated purchased inprocess research development also recorded income tax benefit million related reduction valuation allowance certain net deferred tax assets sold shares common stock osi recognized loss sale marketable securities million shares partial consideration sale oncology assets completed sale oncology assets related technology osi recorded nonoperating gain million also recorded nonoperating gain million sale equity interest proligo llc note adopted sfas nos collectively referred sfas accounting derivative instruments hedging activities first quarter change accounted change accounting principle note february march september gilead implemented twoforone stock splits form stock dividend share per share amounts periods presented restated reflect stock splits note cash dividends declared paid common stock table contents item managements discussion analysis financial condition results operations following managements discussion analysis mda intended help reader understand results operations financial condition gilead mda provided supplement read conjunction financial statements accompanying notes financial statements executive summary gilead experienced another year increasing revenues profits cash flows due successful launches adoption drugs treatment human immunodeficiency virus hiv hepatitis b virus hbv well maintenance product sales ambisome able increase market share due favorable consistent safety efficacy profile demonstrated date products including viread truvada emtriva increase market share hiv products helped contribute increase hiv product sales billion continued adoption hepsera increased product sales million increase intend build upon successes products continuing engage longterm clinical studies differentiate products additionally within hiv franchise intend work patients physicians key opinion leaders educate benefits earlier treatment expected help expand treatedpatient population continue gather positive data safety efficacy truvada launched various european countries believe uptake truvada continue driving force increasing hiv product sales last years also focused creating believe solid foundation longterm growth looking opportunities acquire inlicense innovative technologies drug candidates developing technologies alongside inhouse initiatives entered collaboration japan tobacco inc japan tobacco made advances phase clinical trial based hiv integrase inhibitor licensed additionally demonstrated bioequivalence formulation fixeddose combination truvada bristolmyers squibb companys bms sustiva triple product well began dosing patients phase study hcv drug candidate licensed achillion pharmaceuticals internally made significant progress enrollment two phase studies comparing efficacy safety tenofovir versus hepsera patients hbv also filed investigational new drug application december gs one internal integrase clinical candidates initiated phase clinical study healthy volunteers february intend sustain longterm growth business continuing discover commercialize new drugs antivirals area especially hiv hepatitis c virus hcv areas also plan exploring therapeutic areas significant unmet medical needs licensing acquisition opportunities fit core competencies complement longterm growth strategy part ability grow consists building strong global organization year relocated european commercial medical administrative headquarters france united kingdom thereby uniting functions regulatory safety information technology groups already headquartered united kingdom also made strategic expansion global sales marketing activities revenues continued increase continued see collection improvements certain european regions last two years cash investment management continued important priority addition reexamining cash investments portfolio investment policies strategies also used cash various collaborative activities third quarter along royalty pharma purchased royalty interest owned emory university emtricitabine million furthermore december leveraging strong financial position results entered million credit facility syndicate banks consisting million term loan million revolving credit facility term loan used facilitate onetime repatriation qualified foreign earnings american jobs creation act ajca resulted million income tax benefit recorded yet drawn amounts revolving facility facility give us flexibility use table contents funds future corporate development initiatives including licensing opportunities potential acquisitions allowing us meet ongoing working capital infrastructure needs focus continue building upon current infrastructure continuing advance drug candidates clinic executing operational goals promoting products safety efficacy data drive higher patient adoption also intend build stronger working relationship f hoffmannla roche ltd roche respect tamiflu amended agreement jointly drive effective marketing supply chain strategies meet increasing demand tamiflu also focus significant resources preparing launch coformulated truvadasustiva product united states moreover working merck co inc merck bms arrangements launch coformulated product outside united states finally continue strengthen global infrastructure better support growing employee customer base including expanding certain aspects manufacturing capabilities well upgrading facilities information systems critical accounting policies estimates judgments discussion analysis financial condition results operations based consolidated financial statements prepared accordance us generally accepted accounting principles preparation financial statements requires us make estimates judgments affect reported amounts assets liabilities revenues expenses related disclosures ongoing basis evaluate estimates including related revenue recognition allowance doubtful accounts inventories prepaid royalties clinical trial accruals tax provision base estimates historical experience various marketspecific assumptions believed reasonable circumstances results form basis making judgments carrying values assets liabilities readily apparent sources actual results however may differ significantly estimates believe following critical accounting policies reflect significant judgments estimates used preparation consolidated financial statements revenue recognition recognize revenue product sales persuasive evidence arrangement exists delivery customer occurred price fixed determinable collectibility reasonably assured record estimated reductions revenue expected returns expired products distributor fees government rebate programs medicaid reimbursements customer incentives cash discounts prompt payment estimates distributor fees based contractually determined fixed percentages sales estimates government rebate programs cash discounts based contractual terms historical utilization rates expectations regarding future utilization rates programs estimates product returns including new products based ongoing analysis industry historical return patterns includes monitoring feedback receive sales force regarding customer use satisfaction reviewing inventory data available us inventory management agreements us wholesalers assist us monitoring channel inventory levels purchasing thirdparty data monitor prescriptions well new products comparing products products similar sales channels monitor activities clinical trials key competitors assess potential impact future sales return expectations necessary expected returns marketed drugs generally low shelf lives products united states ranges months truvada hepsera months viread ambisome conditions become competitive markets served drugs circumstances change may take actions increase product return estimates may offer additional customer incentives would result incremental reduction future revenue time return estimate changed new incentives offered contract revenue research development rd recorded performance occurs earnings process completed based performance requirements contract nonrefundable contract fees performance obligations exist continuing involvement gilead recognized earlier occur payments received collection reasonably assured table contents revenues nonrefundable upfront license fees milestone payments continue involvement development collaboration obligation supply product recognized performance occurs obligations completed accordance specific terms gileads obligations types arrangements revenues recognized obligation fulfilled ratably development manufacturing period revenues associated substantive atrisk milestones recognized based upon achievement milestones defined respective agreements advance payments received excess amounts earned classified deferred revenue allowance doubtful accounts also maintain allowance doubtful accounts estimated losses resulting inability customers make required payments allowance based analysis several factors including limited contractual payment terms historical payment patterns customers individual customer circumstances analysis days sales outstanding customer geographic region review local economic environment potential impact government funding reimbursement practices financial condition customers economic environment operate deteriorate resulting inability make payments additional allowances may required allowance doubtful accounts balance percentage total accounts receivable materially change december december believe allowance doubtful accounts adequate cover anticipated losses current conditions however significant deterioration factors especially respect government funding reimbursement practices european market could materially change expectations result increase allowance doubtful accounts inventories record write downs value inventory based review historical quantity bad batches experienced manufacturing process expectations production inventory levels also perform quality control reviews individual raw material batches generally record inventory writeoffs relating estimated obsolescence risk competition primarily shelf life products long however current assumptions future production inventory levels demand competition change actual market conditions less favorable projected management additional inventory writedowns may required could negatively impact product gross margins results operations prepaid royalties capitalize royalties prepaid cost specifically related emtricitabine royalties paid emory hiv indication based present value future royalty obligation would expect pay emory assuming certain expected levels product sales incorporating emtricitabine technology net book value prepaid asset determined using best estimate relevant future product sales available time consummated transaction however review least annually expected future performance products indicators would support writedown net recoverable value asset amortize prepaid royalties based effective royalty rate derive forecasted hiv product sales incorporating emtricitabine product sales forecasts prepared annually determined using best estimates future activity previously unanticipated significant change occurs sales forecasts including introduction competing product us one competitors hiv market emtricitabine would prospectively update royalty rate used amortize prepaid royalties may increase future royalty expense review royalty rate least annually would adjust rate based significant new facts circumstances may arise clinical trial accruals record accruals estimated clinical study costs clinical studies performed third party contract research organizations cros costs significant component rd expenses table contents incurred cro costs million million million respectively accrue costs clinical studies performed cros straightline basis service periods specified contracts adjust estimates required based upon ongoing review level effort costs actually incurred cro validate accruals quarterly vendors perform detailed reviews activities related significant contracts based upon results validation processes assess appropriateness accruals make adjustments deem necessary ensure expenses reflect actual effort incurred cros generally significant portion total clinical trial costs associated start activities trial patient enrollment gilead extensively outsources clinical trial activities usually performs small portion startup activities inhouse result cros typically perform total startup activities trials including document preparation site identification screening preparation prestudy visits training program management budgeted basis costs typically total contract value actual basis percentage range significantly wider many contracts either expanded reduced scope compared original budget startup costs particular trial change significantly startup costs usually occur within months contract executed milestone event driven nature remaining activities related costs patient monitoring administration generally occur ratably throughout life individual contract study contracts negotiated fixed unit prices vary length six months single dose phase study two years complex phase study average length contracts upper end range order provide longterm safety efficacy data support commercial launches viread truvada hepsera emtriva material cro contracts terminable us upon written notice gilead generally liable actual effort expended cro point time contract regardless payment status amounts paid advance services performed refunded contract terminated december differences actual estimated activity levels particular study significant enough require material adjustment however management receive complete accurate information vendors underestimated activity levels associated study given point time would record additional potentially significant rd expenses future periods tax provision estimate income tax provision including deferred tax assets liabilities based significant management judgment evaluate realization portion deferred tax assets quarterly basis record valuation allowance reduce deferred tax assets amounts likely realized consider future taxable income ongoing tax planning strategies historical financial performance assessing need valuation allowance expect realize deferred tax assets previously recorded valuation allowance would reduce valuation allowance period determination first made adjustments made fourth quarter determined likely certain deferred tax assets would realized therefore released related valuation allowance resulted income tax benefit approximately million million respectively similarly determine would able realize part deferred tax assets valuation allowance would increase valuation allowance period determination first made future effective income tax rate may affected factors changes tax laws regulations andor rates changing interpretation existing laws regulations changes international organization changes overall levels income tax management discussed development selection critical accounting policies audit committee gileads board directors audit committee reviewed disclosures presented relating table contents results operations total revenues total revenues billion billion million included total revenues product sales royalty revenue contract revenue including revenue earned manufacturing collaborations product sales product sales consisted following thousands change change hiv products viread truvada emtriva hiv products ambisome hepsera vistide daunoxome total product sales total product sales increased compared compared case primarily due increase volume sales hiv products significant percentage product sales continue denominated foreign currencies use forward contracts hedge percentage forecasted international sales primarily denominated euro reduces eliminate fluctuations sales due changes foreign currency exchange rates hiv products viread truvada emtriva approved sale united states october august july respectively viread truvada emtriva approved sale european union february february october respectively sales truvada commenced united states third quarter countryspecific launches europe began hiv product volume increased compared compared hiv product volume growth united states respectively whereas volume increases outside united states respectively viread sales viread remained relatively consistent sales levels resulting continued strong performance viread offset impact patients switching vireadcontaining regimen one containing truvada countries truvada available sales viread increased compared primarily driven volume increases united states across european countries truvada sales truvada increased united states first full year truvada sales truvada patients come primarily patients new therapy secondarily patients switching regimens including containing viread emtriva table contents emtriva sales emtriva decreased compared primarily driven impact patients switching emtrivacontaining regimen one containing truvada countries truvada available expect sales hiv products range billion billion include future product sales may result triple product approved commercial sale united states predict whether triple product approved us food drug administration fda ambisome ambisome product sales increased compared primarily driven increase overall sales volume partially offset lower pricing regions outside united states product sales increased prior year due primarily higher sales volume outside united states stronger european currency partially offset lower pricing many regions outside united states discussion us ambisome product sales relates solely sales ambisome astellas pharma inc astellas successor fujisawa usa inc recorded manufacturing cost due greater manufacturing efficiencies per unit manufacturing cost ambisome decreased thereby decreasing revenues reported sales astellas royalties earn sales ambisome astellas discussed royalty revenue result pricing pressures europe increased competition expect ambisome product sales range million million hepsera sales hepsera increased compared compared primarily driven sales volume growth europe united states volume also increased respect sales hepsera glaxosmithkline gsk sell hepsera gsk manufacturing cost connection gsks distribution activities asia royalties earn sales hepsera gsk recorded royalty revenue expect hepsera sales range million million takes account impact existing potential competitor products united states europe royalty revenue recorded royalty revenues million compared million million threeyear period significant sources royalty revenues sales tamiflu roche sales ambisome united states astellas november gilead resolved dispute roche relating development license agreement agreed terminate related arbitration pending gilead roche part terms dispute resolution gilead roche established joint committees oversee manufacturing commercial pandemic planning product option copromote tamiflu specialized areas united states related dispute resolution roche also paid us million recognized royalty revenue consisted million relating disputed royalties million relating reimbursement contractual cost goods adjustment previously reduced earned royalties million relating updating royalties payable gilead first nine months based current year royalty rates instead prior years effective royalty rate excluding amounts received connection dispute resolution significant year year increase tamiflu royalties primarily due higher royalties received roche higher tamiflu sales caused significant flu season particularly japan fulfillment orders pandemic table contents readiness supplies certain countries royalty revenues earned roche including amounts recognized dispute resolution million million million respectively comparing royalty revenues earned sales tamiflu roche also increased substantially due severe influenza epidemic united states late early increased awareness discussion supply influenza treatments also increased roches sales tamiflu consequently royalties difficult estimate third party product sales similar outlicensing arrangements arrangement astellas royalties recorded one month arrears record royalty revenue roche one quarter arrears royalty revenue earned sales ambisome astellas remained consistent million slight increase million contract revenue total contract revenues million compared million million contract revenues consisted primarily million milestone payment earned osi pharmaceuticals inc osi successor eyetech pharmaceuticals inc upon first commercial sale macugen united states well revenue earned various contract manufacturing projects contract revenues consisted primarily million research milestone revenue earned osi included million recognized upon filing new drug applications osi europe united states macugen cost goods sold product gross margin following table indicates total product sales cost goods sold thousands product gross margin change change total product sales cost goods sold product gross margin product gross margin slightly lower due product mix changes patients continue switch viread higher margin product truvada product gross margin relatively consistent positive impact improvements certain manufacturing processes favorable foreign currency environment offset changes product sales mix result royalty pharma purchase royalty interest owned emory emtricitabine july capitalized million prepaid royalties representing share million purchase price third quarter begun amortize prepaid royalty cost goods sold remaining life underlying patent based effective royalty rate derived forecasted sales recorded royalties royalty pharma based actual emtricitabine net sales relative royalty pharmas ownership interest underlying emory royalty interest although expect transaction favorable impact emtricitabine product gross margin longterm impact overall product gross margin significant expect product gross margin generally consistent excludes impact potential launch triple product predict whether triple product approved fda although expect launch triple product decrease product gross margin percentage impact net profit due fact majority owner table contents joint venture bms consolidate triple product revenue however earn full product margin truvada portion triple product earn zero product margin sustiva portion triple product research development expenses following table summarizes rd expenses major components thousands change change research clinical development pharmaceutical development total rd expenses consist primarily personnel costs including salaries benefits clinical studies performed cros materials supplies licenses fees overhead allocations consisting various support facilities related costs rd activities separated three main categories research clinical development pharmaceutical development research costs typically consist preclinical toxicology costs clinical development costs include costs phase clinical trials pharmaceutical development costs consist product formulation chemical analysis costs million increase rd expenses compared primarily attributable million payment made emory connection amendment existing license agreement emory related obligation develop emtricitabine hepatitis b indication million payment made japan tobacco related execution hiv integrase license agreement gs increased salaries additional headcount million increased clinical product development activities associated hcv hbv hiv programs payments made emory japan tobacco expensed underlying technology incomplete alternative future use case emory significant rd activities expected next several years million increase rd expenses compared primarily attributable increased salaries million due largely higher headcount million research license fees paid relation hcv collaboration agreements entered achillion pharmaceuticals achillion genelabs technologies genelabs well increased cro costs million associated increased clinical activities payments made achillion genelabs expensed underlying technology alternative future use increase rd expenses compared partially offset decrease spending due discontinuation two internal programs gs gs focused development certain hiv investigational products rd expenses included reimbursement gilead million settlement contractual dispute vendor expect rd expenses increase levels reflecting increased spending internal collaborative rd efforts relating expectation pipeline products progress advanced clinical trials increased headcount well impact expensing sharebased payments selling general administrative expenses following table summarizes sga expenses thousands change change selling general administrative table contents sga expenses million increase million compared significant increase primarily due increase salaries million due largely higher headcount increase market research speakers programs symposia costs million million severance relocation expenses associated relocation european commercial medical administrative headquarters france united kingdom increase medical education costs million increase journal advertising costs million well general expansion sales marketing activities worldwide increases partially offset decrease bad debt expense million result higher collections certain european countries sga expenses million compared million includes reclassification phase clinical trial expenses rd mentioned significant increase expenses compared primarily related increase salaries million due largely higher headcount increase consulting fees million related sarbanesoxley compliance business strategy consulting well increase costs million relating speakers programs grants journal advertising remainder increase sga expenses compared generally due increased global marketing efforts expanded infrastructure required support growth business part infrastructure investments implemented reorganization sales marketing functions newly created commercial division conjunction reorganization created filled new position executive vicepresident commercial operations responsible global commercial operations strategy product portfolio expect sga expenses increase primarily due anticipated costs associated launching supporting truvada various countries costs related ongoing investment global commercial organization hiring promotional programs well impact expensing share based payments purchased inprocess research development connection acquisition net assets triangle pharmaceuticals inc triangle completed january recorded purchased inprocess rd expenses million first quarter charge due triangles incomplete rd programs yet reached technological feasibility alternative future use acquisition date value purchased inprocess rd determined estimating related future net cash flows using present value risk adjusted discount rate discount rate significant assumption based estimated weighted average cost capital adjusted upward risks associated projects acquired projected cash flows acquired projects based estimates revenues operating profits related projects considering stage development potential product acquired time resources needed complete development approval product life potential commercialized product associated risks including inherent difficulties uncertainties developing drug compound including obtaining fda regulatory approvals risks related viability potential alternative treatments future target markets table contents summary programs acquisition date follows updated subsequent changes status development estimated acquisition date fair value program description status development millions emtricitabine hiv nucleoside analogue four phase studies completed prior shown inhibitor hiv acquisition date us marketing approval received replication patients fda july emtriva european union approval received european commission october emtricitabinetenofovir df fixed dose fixeddose coformulation tenofovir acquisition date work combination hiv therapy emtricitabine commenced potential coformulation except extent work emtricitabine single agent progressing march applications marketing approval submitted united states european union august marketing approval united states received fda truvada fixeddose coformulation tenofovir emtricitabine marketing approval european union received february sales commenced later first quarter amdoxovir hiv purine dioxolane nucleoside may program phase trials acquisition offer advantages marketed date terminated licensing agreement nucleosides activity emory university university drug resistant viruses georgia research foundation inc exhibited patients hiv infection development discontinued clevudine hbv pyrimidine nucleoside analogue program phase trials acquisition shown inhibitor date august licensing agreement hbv replication patients chronically bukwang pharm ind co ltd terminated infected hbv development discontinued emtricitabine hbv inhibitor hbv replication program phase trials acquisition patients chronically infected hbv date completed december continue evaluate strategy development emtricitabine hepatitis b indication currently expect undertake significant rd activities next several years table contents asset impairment recorded asset impairment charge million certain longlived assets primarily leasehold improvements manufacturing laboratory equipment noncash charge driven decision december terminate liposomal rd activities san dimas discontinue daunoxome product line impairment based analysis undiscounted cash flows generated affected assets compared carrying value carrying value exceeded related estimated undiscounted cash flows wrote carrying value longlived assets estimated fair value subsequent decision discontinue daunoxome product line received unanticipated requests europe asking gilead reconsider selling daunoxome result requests management decided continue selling product certain countries although evaluating supply sales strategy respect daunoxome accordance us generally accepted accounting principles new cost basis impaired assets adjusted new facts circumstances gain warrant pursuant agreement eyetech pharmaceuticals inc eyetech predecessor osi entered march received warrant purchase shares eyetech series b convertible preferred stock exercisable price per share january eyetech completed initial public offering common stock time adjusted fair value warrant resulting gain million time fair value warrant estimated using blackscholes valuation model volatility rate discount rate end first quarter exercised warrant net basis using shares eyetech common stock consideration exercise price subsequently held shares eyetech common stock second quarter sold eyetech shares owned realized gain approximately million included interest income net makewhole payment convertible debt redemption october called redemption outstanding convertible senior notes due december november convertible senior notes called provisional redemption based upon market price gilead common stock exceeding certain thresholds aggregate principal amount outstanding notes million convertible senior notes redeemable redemption price equal principal amount notes plus cash payment equal accrued unpaid interest redemption date cash makewhole payment equal per principal value notes less interest actually paid accrued unpaid date issuance notes redemption date interest convertible senior notes ceased accrue redemption date remaining right holders thereafter receive redemption payment including accrued unpaid interest redemption date makewhole payment alternatively note holders could elect convert notes shares gilead common stock price per share shares gilead common stock per principal amount notes holders substantially outstanding notes converted notes shares gilead common stock prior november redemption date result conversions shares common stock issued note holders connection redemption made aggregate makewhole payments million note holders interest income net recorded interest income net million million million increases primarily attributable higher cash balances previous year interest income depend principally upon prevailing interest rates level cash cash equivalent marketable securities balances table contents interest expense incurred interest expense million compared million million decrease primarily attributable conversion million convertible senior notes shares common stock november decrease primarily due conversion million convertible subordinated notes shares common stock december expect interest expense increase result interest paying million fiveyear term loan entered december minority interest joint venture minority interest reflects bmss interest operating results joint venture bms united states operations joint venture commenced activities primarily focusing triple product achieving bioequivalence various coformulations achievement successful formulation fourth quarter expect significant increase activities especially fda commercial approval obtained provision benefit income taxes provision benefit income taxes million million million respectively effective income tax rate differs us federal statutory rate due generally recognition previously unbenefitted net operating losses tax credit carryforwards certain earnings operations jurisdictions lower tax rates united states jurisdictions us taxes provided earnings planned reinvested indefinitely outside united states benefit derived qualifying dividend made american jobs creation act ajca partially offset state taxes october ajca signed law ajca allows deduction certain qualified foreign earnings repatriated defined ajca elected apply provision qualifying earnings repatriated earnings repatriation resulted onetime tax provision benefit approximately million includes reversal deferred tax liability previously accrued unremitted foreign earnings million december effective income tax rate differs us federal statutory rate due generally recognition previously unbenefitted net operating losses tax credit carryforwards certain earnings operations jurisdictions lower tax rates united states jurisdictions us taxes provided earnings planned reinvested indefinitely outside united states partially offset state taxes tax benefit includes reversal valuation allowance certain deferred tax assets december concluded likely would realize portion benefit related deferred tax assets accordingly reduced valuation allowance assets recorded tax benefit million recognition deferred tax assets impact cash flows partially offsetting recorded tax benefit income tax expense associated income earned foreign subsidiaries foreign losses lower tax rates nontax deductibility purchased inprocess rd significant net operating loss carryforwards used reduce us tax liability excluding benefit relating reversal valuation allowance write purchased inprocess rd effective tax rate table contents liquidity capital resources following table summarizes cash cash equivalents marketable securities working capital statements cash flows thousands december cash cash equivalents marketable securities working capital year ended december cash provided used operating activities investing activities financing activities cash cash equivalents marketable securities cash cash equivalents marketable securities totaled billion december increase december cash cash equivalents marketable securities totaled billion december increase december increase billion million primarily due net cash provided operations million million proceeds issuance stock employee stock plans million million proceeds issuance longterm debt million increases partially offset capital expenditures million million working capital working capital december billion compared billion december significant factors resulted increase working capital billion increase cash cash equivalents marketable securities million increase accounts receivable primarily due increased sales partially offset improved collection activity especially certain european countries collections traditionally slower million increase inventories meet growing demand hiv products hepsera well meet gilead access program requirements million increase deferred tax assets million increase prepaids current assets primarily related current portion prepaid royalties emory emtricitabine increases partially offset million increase income taxes payable primarily due higher profitability partially offset tax benefits employee stock plans million increase reflecting current portion million term loan entered december table contents million increase accrued liabilities including increases accruals related medicaid rebates royalty expenses sales marketing expenses rent expenses partially offset decrease liability associated fair value forward currency contracts us dollar strengthened euro working capital december billion compared billion december significant factors resulted increase working capital million increase cash cash equivalents marketable securities million increase accounts receivable primarily due increased sales viread united states europe sales new product truvada launched united states latter half million increase inventories primarily due increase purchase raw materials production viread truvada inventory meet increasing sales demand increases working capital partially offset million decrease current deferred tax assets primarily due utilization net operating losses tax credit carryforwards offset taxable income million increase current liabilities including million increase medicaid rebate obligations million increase deferred revenue primarily due royalties received roche million increase liability associated fair value forward currency contracts us dollar continued weaken euro million increase accounts payable primarily due increases raw material purchases support viread truvada sales growth cash provided operating activities cash provided operating activities primarily driven increases net income expected continue primary recurring source cash increase cash provided operating activities year ended december million primarily attributed product sales growth increased cash collections customers well payments received related resolution dispute roche partially offset million prepaid royalties made emory cash used investing activities cash used investing activities primarily related purchases sales maturities availableforsale securities capital expenditures used million cash investing activities compared million million increases cash used investing activities primarily due increases cash cash equivalents balances year year net cash used investing activities purchases availableforsale securities increased million compared million million cash used investing activities higher compared due million paid acquisition triangles net assets million paid purchase foster city facilities capital expenditures made related primarily expanding certain aspects manufacturing capabilities well upgrading facilities capital expenditures primarily facilities improvements including approximately million associated completion pilot plant foster city used develop drug processes prepare materials supply clinical trials well additional spending laboratory manufacturing equipment accommodate growth table contents cash provided financing activities cash provided financing activities primarily related proceeds million term loan well stock option exercises stock purchases made employee stock plans also received million million million respectively relating stock option exercises stock purchases employee stock purchase plan believe existing capital resources supplemented cash generated operations adequate satisfy capital needs foreseeable future future capital requirements depend many factors including commercial performance current future products progress scope rd efforts including preclinical studies clinical trials cost timing outcome regulatory reviews expansion sales marketing capabilities administrative expenses possibility acquiring manufacturing capabilities additional office facilities possibility acquiring companies new products establishment additional collaborative relationships companies defense costs associated settlements adverse results litigation may future require additional funding could form proceeds equity debt financings universal shelf registration statement filed december potential issuance million securities funding required assure available favorable terms december entered agreement syndicate banks provide fiveyear million senior credit facility million facility comprised uncollateralized million term loan uncollateralized million revolving credit facility proceeds term loan used december facilitate qualified intercompany cash dividend distribution million gilead biopharmaceutics ireland corporation gbic whollyowned irish subsidiary gilead us parent company gilead sciences inc part repatriation qualified foreign earnings provisions ajca terms million term loan minimum principal payments repaid end calendar quarter beginning march million december amounts outstanding million revolving credit facility capacity revolving credit facility increase maximum million million term loan repaid ability irrevocably cancel unutilized portion revolving credit facility whole part offbalance sheet arrangements offbalance sheet arrangements currently material reasonably likely material financial position results operations contractual obligations contractual obligations consist capital operating leases well purchase obligations primarily form capital commitments purchase obligations active pharmaceutical ingredients inventoryrelated items clinical trials contracts following table summarizes enforceable legally binding obligations future commitments obligations related contracts likely continue regardless table contents fact cancelable december following table summarizes contractual obligations december thousands payments due period less one contractual obligations total year years years years term loan capital lease obligations operating lease obligations capital commitments purchase obligations clinical trials total december longterm debt consists million year term loan entered fourth quarter december firm capital project commitments approximately million relating facilities improvement addition budgeted significant capital expenditures mainly due anticipated increased infrastructure needs higher rd spending may capital spending future years december firm commitments purchase active pharmaceutical ingredients inventoryrelated items amounts disclosed represent minimum purchase requirements actual purchases expected significantly exceed amounts december several clinical studies various clinical trial phases significant clinical trial expenditures cros although contracts cros cancelable generally cancelled contracts amounts reflect commitments based existing contracts reflect future modifications existing contracts anticipated potential new contracts recent accounting pronouncements december fasb issued sfas revised sharebased payment sfas r revision sfas sfas r supersedes accounting principles board opinion apb amends sfas statement cash flows sfas r requires sharebased payments employees directors including grants stock options recognized income statement based fair values beginning first quarterly period june early adoption permitted april securities exchange commission adopted new rule amended compliance date sfas r allowed adopt new standard effective january pro forma disclosures previously permitted sfas longer alternative financial statement recognition sfas r adopted sfas r january sfas r must determine appropriate fair value model related assumptions used valuing sharebased payments amortization method compensation cost transition method used date adoption transition methods include modified prospective retroactive adoption methods modified prospective method requires compensation expense recorded unvested stock options restricted stock beginning first quarter adoption sfas r retroactive methods would record compensation expense unvested stock options restricted stock beginning first period restated determined adopt modified prospective method continue use black scholes option valuation model based preliminary analysis expect adoption sfas r material impact income statement earnings per share currently estimate impact approximately per diluted share sfas r also requires benefit tax deductions excess recognized compensation cost reported statement cash flows financing cash flow rather operating cash flow required current accounting literature requirement reduce net operating cash flows increase net financing cash flows periods adoption table contents item quantitative qualitative disclosures market risk foreign currency exchange risk operations include manufacturing sales activities united states well sales activities countries outside united states including europe australia result financial results could significantly affected factors changes foreign currency exchange rates weak economic conditions foreign markets distribute products operating results exposed changes exchange rates us dollar various foreign currencies significant euro british pound australian dollar us dollar strengthens currencies relative value sales made respective foreign currency decreases conversely us dollar weakens relative amounts sales increase overall net receiver foreign currencies therefore benefit weaker us dollar adversely affected stronger us dollar relative foreign currencies transact significant amounts business enter foreign exchange forward contracts mitigate impact changes currency exchange rates cash flows sales denominated foreign currency well foreign currencydenominated net monetary assets liabilities significant percentage product sales denominated foreign currencies increases value us dollar foreign currencies past reduced future may reduce us dollar return sales negatively impact financial condition use forward contracts hedge percentage forecasted international sales primarily denominated euro currency recent years foreign currency exchange fluctuations positively negatively impacted product sales gross margin however full impact foreign currency fluctuations moderated hedge program following table summarizes notional amounts average currency exchange rates fair values open foreign exchange forward contracts december contracts maturities one year less average rates stated terms amount foreign currency per us dollar fair values represent estimated settlement amounts december notional amounts fair values us dollars thousands currency notional amount average rate fair value british pound euro australian dollar total total notional amount million fair value million open foreign exchange forward contracts december compares total notional amount million fair value million open foreign exchange forward contracts december significant increase notional amount outstanding contracts primarily attributed projected increase product sales forecasted periods interest rate risk portfolio availableforsale investment securities variablerate liabilities create exposure interest rate risk respect investment portfolio adhere investment policy requires us limit amounts invested securities based duration industry group investment type issuer except securities issued us government goals investment policy order priority follows safety preservation principal diversification risk table contents liquidity investments sufficient meet cash flow requirements competitive aftertax rate return following table summarizes expected maturities average interest rates interestgenerating assets interestbearing liabilities december dollars thousands years ending december total fair value december thereafter assets availableforsale securities average interest rate liabilities longterm debt including current portion average interest rate longterm obligations including current portion average interest rate longterm debt consists million year term loan entered fourth quarter average interest rates based implied forward rates yield curve reporting date terms loan minimum principal amount repaid end calendar quarter beginning march million interest accrued rate libor plus tiered contractual rate basis points prepay term loan time whole part together accrued interest prepaid principal without penalty premium outstanding interest principal december payable demand longterm obligations consist capital leases operating leases net noncancelable subleases interest portion payments due included international credit risk accounts receivable balance december million compared million december growth accounts receivable balances primarily due higher product sales viread truvada united states europe certain countries payments typically slow primarily greece italy portugal spain accounts receivable balances significant cases slow payment practices reflect pace governmental entities reimburse customers turn may increase credit risk related certain customers sales customers countries tend relatively slow paying past increased future may increase average length time accounts receivable outstanding december past due accounts receivable greece italy portugal spain totaled million million days past due based contractual terms receivables date experienced significant losses respect collection accounts receivable believe substantially accounts receivable balances collectible perform credit evaluations customers financial condition generally required collateral item financial statements supplementary data financial statements required item set forth beginning report incorporated herein reference table contents item changes disagreements accountants accounting financial disclosure applicable item controls procedures evaluation disclosure controls procedures evaluation december carried supervision participation management including chief executive officer chief financial officer effectiveness design operation disclosure controls procedures defined sec rules controls procedures company designed ensure information required disclosed company reports files securities exchange act exchange act recorded processed summarized reported within required time periods based upon evaluation chief executive officer chief financial officer concluded disclosure controls procedures effective b managements report internal control financial reporting management responsible establishing maintaining adequate internal control financial reporting term defined securities exchange act rule af internal control system designed provide reasonable assurance regarding preparation fair presentation financial statements external purposes accordance generally accepted accounting principles internal control systems matter well designed inherent limitations provide reasonable assurance objectives internal control system met supervision participation management including chief executive officer chief financial officer conducted evaluation effectiveness internal control financial reporting based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission coso based evaluation concluded internal control financial reporting effective december independent registered public accounting firm ernst young llp audited consolidated financial statements included annual report issued report managements assessment internal control financial reporting well effectiveness internal control financial reporting december report audit internal control financial reporting appears table contents report independent registered public accounting firm board directors stockholders gilead sciences inc audited managements assessment included accompanying managements report internal control financial reporting included item gilead sciences inc maintained effective internal control financial reporting december based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission coso criteria gilead sciences incs management responsible maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting responsibility express opinion managements assessment opinion effectiveness gilead sciences incs internal control financial reporting based audit conducted audit accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether effective internal control financial reporting maintained material respects audit included obtaining understanding internal control financial reporting evaluating managements assessment testing evaluating design operating effectiveness internal control performing procedures considered necessary circumstances believe audit provides reasonable basis opinion companys internal control financial reporting process designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles companys internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition companys assets could material effect financial statements inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate opinion managements assessment gilead sciences inc maintained effective internal control financial reporting december fairly stated material respects based coso criteria also opinion gilead sciences inc maintained material respects effective internal control financial reporting december based coso criteria also audited accordance standards public company accounting oversight board united states consolidated balance sheets gilead sciences inc december related consolidated statements operations stockholders equity cash flows three years period ended december related financial statement schedule report dated february expressed unqualified opinion thereon ernst young llp palo alto california february table contents c changes internal control financial reporting management including chief executive officer chief financial officer evaluated changes internal control financial reporting occurred quarter ended december concluded change quarter materially affected reasonably likely materially affect internal control financial reporting item b information applicable part iii item directors executive officers registrant information required item concerning directors executive officers incorporated reference sections definitive proxy statement filed sec pursuant regulation connection annual meeting stockholders proxy statement headings nominees executive officers compliance section securities exchange act gileads written code ethics applies directors employees including executive officers code ethics available gileads website httpwwwinvestorsgileadcom corporate governance changes waivers code ethics disclosed website item executive compensation information required item incorporated reference sections proxy statement headings compensation executive officers report compensation committee executive compensation compensation committee interlocks insider participation performance measurement comparison item security ownership certain beneficial owners management related stockholder matters information required item incorporated reference section proxy statement heading security ownership certain beneficial owners management item certain relationships related transactions information required item incorporated reference sections proxy statement headings certain relationships related party transactions compensation executive officers item principal accounting fees services information required item incorporated reference section proxy statement heading principal accounting fees services table contents part iv item exhibits financial statement schedules following documents filed part annual report index list financial statements report independent registered public accounting firm audited consolidated financial statements consolidated balance sheets consolidated statements operations consolidated statement stockholders equity consolidated statements cash flows notes consolidated financial statements schedule ii included report schedules omitted required required information included financial statements notes thereto exhibits following exhibits filed herewith incorporated reference exhibit exhibit footnote number description document asset purchase agreement registrant osi pharmaceuticals inc dated november agreement plan merger among registrant simbolo acquisition sub inc whollyowned subsidiary registrant triangle pharmaceuticals inc dated december restated certificate incorporation registrant amended bylaws registrant amended restated march reference made exhibit exhibit amended restated rights agreement dated october registrant chasemellon shareholder services llc first amendment amended restated rights agreement dated october registrant mellon investor services llc formerly known chasemellon shareholder services llc form indemnity agreement entered registrant directors executive officers form employee proprietary information invention agreement entered registrant certain officers key employees form option agreements used stock option plan letter agreement dated september registrant iocbrega registrants employee stock purchase plan amended july registrants stock option plan amended restated april amended january amended january related agreements registrants nonemployee directors stock option plan amended january amended january including form option agreement thereunder amendment agreement dated october registrant iocbrega table contents exhibit exhibit footnote number description document amendment agreement dated december registrant iocbrega development license agreement among registrant f hoffmannla roche ltd hoffmannla roche inc dated september nexstar pharmaceuticals incs incentive stock plan adopted february amended nexstar pharmaceuticals incs director option plan adopted july lease dated february registrant majestic mapa properties llc lease dated february registrant majestic mapa properties llc lease dated july among registrant majestic realty co majesticmapa properties llc first amendment thereto dated march agreement astellas pharma inc successor fujisawa usa inc registrant successor vestar inc dated august amendment thereto dated may amendment agreement astellas pharma inc successor fujisawa usa inc registrant successor vestar inc april amendment agreement astellas pharma inc successor fujisawa usa inc registrant dated march license distribution agreement dated september dainippon sumitomo pharma co ltd successor sumitomo pharmaceuticals co ltd registrant successor nexstar pharmaceuticals inc settlement agreement dated august among registrant successor nexstar pharmaceuticals inc astellas pharma inc successor fujisawa usa inc liposome company inc amendment dated april sumitomo pharmaceuticals co ltd registrant successor nexstar pharmaceuticals inc license distribution agreement dated september sumitomo registrant successor nexstar pharmaceuticals inc corporate plan retirement select planbasic plan document corporate plan retirement select planadoption agreement addendum gilead sciences inc deferred compensation plan licensing agreement dated april gilead world markets limited glaxo group limited triangle pharmaceuticals inc stock incentive plan exclusive license agreement among registrant successor triangle pharmaceuticals inc glaxo group limited wellcome foundation limited glaxo wellcome inc emory university dated may settlement agreement among registrant successor triangle pharmaceuticals inc emory university dr david w barry glaxo wellcome plc glaxo wellcome inc glaxo group limited wellcome foundation limited dated may settlement exclusive license agreement among registrant successor triangle pharmaceuticals inc shire biochem inc shire pharmaceuticals group plc emory university university georgia research foundation dated august gilead sciences inc severance plan amended may table contents exhibit exhibit footnote number description document lease agreement dated june th registrant gra associates limited llc premises located university drive durham north carolina master clinical commercial supply agreement dated january among gilead world markets ltd registrant patheon inc licensing agreement dated march amended may december april registrant osi pharmaceuticals inc successor eyetech pharmaceuticals inc amendment licensing agreement dated may eyetech pharmaceuticals inc registrant amendment licensing agreement dated december osi pharmaceuticals inc successor eyetech pharmaceuticals inc registrant amendment licensing agreement dated august osi pharmaceuticals inc successor eyetech pharmaceuticals inc registrant amendment dated may licensing agreement dated april glaxo group limited gilead world markets limited amendment dated january licensing agreement dated april glaxo group limited gilead world markets limited employment agreement dated april registrant mark l perry gilead sciences inc equity incentive plan amended may collaboration agreement among registrant gilead holdings llc bristolmyers squibb company er squibb sons llc bristolmyers squibb gilead sciences llc dated december license agreement japan tobacco inc registrant dated march tenofovir disoproxil fumarate manufacturing supply agreement gilead world markets ltd pharmachem technologies grand bahama ltd dated july royalty sale agreement among registrant emory university investors trust custodial services ireland limited solely capacity trustee royalty pharma dated july amended restated license agreement among registrant emory university investors trust custodial services ireland limited solely capacity trustee royalty pharma dated july term loan agreement among gilead biopharmaceutics ireland corporation lenders party thereto bank america na administrative agent dated december parent guaranty agreement registrant dated december subsidiary guaranty agreement dated december gilead vintage park llc credit agreement among registrant lenders party thereto bank america na administrative agent swing line lender lc issuer dated december subsidiary guaranty agreement gilead vintage park llc dated december base salaries named executive officers form employee stock option agreement used equity incentive plan table contents exhibit exhibit footnote number description document form nonemployee stock option agreement used equity incentive plan corporate bonus plan code section bonus plan first amendment supplement dated november development licensing agreement among registrant f hoffmannla roche ltd hoffmanla roche inc dated september restated amended toll manufacturing agreement among gilead sciences limited registrant altana pharma oranienburg gmbh dated november subsidiaries gilead sciences inc consent independent registered public accounting firm power attorney reference made signature section certification section certification section certification filed exhibit registrants current report form k filed january incorporated herein reference filed exhibit registrants current report form k filed december incorporated herein reference filed exhibit registrants registration statement form filed july incorporated herein reference filed exhibit registrants annual report fiscal year ended december incorporated herein reference filed exhibit registrants current report form k filed october incorporated herein reference filed exhibit registrants current report form k filed october incorporated herein reference filed exhibit registrants registration statement form amended incorporated herein reference filed exhibit registrants registration statement form filed january incorporated herein reference filed exhibit registrants annual report fiscal year ended march incorporated herein reference filed exhibit registrants fiscal year ended december incorporated herein reference filed exhibit registrants quarterly report form q quarter ended september incorporated herein reference filed exhibit nexstar pharmaceuticals incs quarterly report form q quarter ended june incorporated herein reference filed exhibit nexstar pharmaceuticals incs form q quarter ended september incorporated herein reference filed exhibit registrants fiscal year ended december incorporated herein reference filed exhibit nexstar pharmaceuticals incs fiscal year ended december incorporated herein reference table contents filed exhibit nexstar pharmaceuticals incs form q quarter ended march incorporated herein reference filed exhibit nexstar pharmaceuticals incs fiscal year ended december incorporated herein reference filed exhibit nexstar pharmaceuticals incs fiscal year ended december incorporated herein reference filed exhibit nexstar pharmaceuticals incs form q quarter ended september incorporated herein reference filed exhibit nexstar pharmaceuticals incs form q quarter ended june incorporated herein reference filed exhibit registrants fiscal year ended december incorporated herein reference filed exhibit registrants quarterly report form q quarter ended june incorporated herein reference filed exhibit registrants registration statement form filed january incorporated herein reference filed exhibit triangle pharmaceuticals incs quarterly report form q quarter ended september incorporated herein reference filed exhibit triangle pharmaceuticals incs current report form k filed september incorporated herein reference filed exhibit registrants quarterly report form q quarter ended june incorporated herein reference filed exhibit registrants fiscal year ended december incorporated herein reference filed exhibit registrants quarterly report form q quarter ended march incorporated herein reference filed exhibit registrants definitive proxy statement filed pursuant regulation connection registrants annual meeting stockholders incorporated herein reference filed exhibit registrants annual report fiscal year ended december incorporated herein reference filed exhibit registrants form q quarter ended march incorporated herein reference filed exhibit registrants form q quarter ended september incorporated herein reference filed exhibit registrants current report form k filed december incorporated herein reference filed exhibit registrants current report form k filed january incorporated herein reference filed exhibit registrants current report form k filed february incorporated herein reference management contract compensatory plan arrangement required filed pursuant item b certain confidential portions exhibit omitted means marking portions asterisk mark exhibit filed separately secretary sec without mark pursuant registrants application requesting confidential treatment rule b securities exchange act table contents gilead sciences inc consolidated financial statements years ended december contents report independent registered public accounting firm audited consolidated financial statements consolidated balance sheets consolidated statements operations consolidated statement stockholders equity consolidated statements cash flows notes consolidated financial statements table contents report independent registered public accounting firm board directors stockholders gilead sciences inc audited accompanying consolidated balance sheets gilead sciences inc december related consolidated statements operations stockholders equity cash flows three years period ended december audits also included financial statement schedule listed index item financial statements schedule responsibility management gilead sciences inc responsibility express opinion financial statements schedule based audits conducted audits accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether financial statements free material misstatement audit includes examining test basis evidence supporting amounts disclosures financial statements audit also includes assessing accounting principles used significant estimates made management well evaluating overall financial statement presentation believe audits provide reasonable basis opinion opinion financial statements referred present fairly material respects consolidated financial position gilead sciences inc december consolidated results operations cash flows three years period ended december conformity us generally accepted accounting principles also opinion related financial statement schedule considered relation basic financial statements taken whole presents fairly material respects information set forth therein also audited accordance standards public company accounting oversight board united states effectiveness gilead sciences incs internal control financial reporting december based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission report dated february expressed unqualified opinion thereon ernst young llp palo alto california february table contents gilead sciences inc consolidated balance sheets thousands except per share amounts december assets current assets cash cash equivalents marketable securities accounts receivable net allowances december december inventories deferred tax assets prepaid expenses current assets total current assets property plant equipment net noncurrent portion prepaid royalties noncurrent deferred tax assets noncurrent assets liabilities stockholders equity current liabilities accounts payable accrued clinical preclinical expenses accrued compensation employee benefits income taxes payable accrued liabilities deferred revenue current maturities longterm debt longterm obligations due within one year total current liabilities longterm deferred revenue longterm debt longterm obligations due one year minority interest joint venture commitments contingencies stockholders equity preferred stock par value per share shares authorized none outstanding common stock par value per share shares authorized shares issued outstanding december respectively additional paidin capital accumulated comprehensive income loss deferred stock compensation retained earnings accumulated deficit total stockholders equity see accompanying notes table contents gilead sciences inc consolidated statements operations thousands except per share amounts year ended december revenues product sales royalty revenue contract revenue total revenues costs expenses cost goods sold research development selling general administrative purchased inprocess research development asset impairment total costs expenses income loss operations gain warrant makewhole payment convertible debt redemption interest income net interest expense minority interest joint venture income loss provision benefit income taxes provision benefit income taxes net income loss net income loss per sharebasic shares used per share calculationbasic net income loss per sharediluted shares used per share calculationdiluted see accompanying notes table contents gilead sciences inc consolidated statement stockholders equity thousands common stock accumulated retained additional comprehensive earnings total paidin income deferred stock accumulated stockholders shares amount capital loss compensation deficit equity balance december net loss unrealized loss availableforsale securities net tax foreign currency translation adjustment unrealized loss cash flow hedges net tax comprehensive loss conversion convertible subordinated debt net acquisition triangle pharmaceuticals inc issuances employee stock purchase plan stock option exercises net tax benefits employee stock plans amortization deferred stock compensation compensatory stock transactions balance december net income unrealized loss availableforsale securities net tax foreign currency translation adjustment unrealized loss cash flow hedges net tax comprehensive income conversion convertible senior notes net debt issuance costs issuances employee stock purchase plan stock option exercises net tax benefits employee stock plans amortization deferred stock compensation compensatory stock transactions balance december net income unrealized loss availableforsale securities net tax foreign currency translation adjustment unrealized gain cash flow hedges net tax comprehensive income issuances employee stock purchase plan stock option exercises net tax benefits employee stock plans amortization deferred stock compensation compensatory stock transactions balance december see accompanying notes table contents gilead sciences inc consolidated statements cash flows thousands year ended december operating activities net income loss adjustments reconcile net income loss net cash provided operating activities depreciation amortization purchased inprocess research development asset impairment loss disposal property plant equipment gain warrant deferred tax assets tax benefits employee stock plans minority interest joint venture noncash transactions changes operating assets liabilities accounts receivable net inventories prepaid royalties prepaid expenses assets accounts payable income taxes payable accrued liabilities deferred revenue net cash provided operating activities investing activities purchases marketable securities proceeds sales marketable securities proceeds maturities marketable securities acquisition triangle net assets net cash acquired acquisition real estate capital expenditures net cash used investing activities financing activities proceeds issuances common stock proceeds longterm debt debt issuance costs repayments longterm debt net cash provided financing activities effect exchange rate changes cash net increase decrease cash cash equivalents cash cash equivalents beginning year cash cash equivalents end year supplemental disclosure cash flow information interest paid income taxes paid noncash investing financing activities common stock issued upon conversion debt reclassification deferred debt issuance costs additional paidin capital upon conversion debt see accompanying notes table contents gilead sciences inc notes consolidated financial statements december organization summary significant accounting policies overview gilead sciences inc gilead company incorporated delaware june biopharmaceutical company discovers develops commercializes therapeutics advance care patients suffering lifethreatening diseases multinational company revenues nine approved products marketing operations twelve countries focus research clinical programs antiinfectives currently market viread tenofovir disoproxil fumarate emtriva emtricitabine truvada emtricitabine tenofovir disoproxil fumarate treatment human immunodeficiency virus hiv infection hepsera adefovir dipivoxil treatment chronic hepatitis b infection ambisome amphotericin b liposome injection treatment fungal infection vistide cidofovir injection treatment cytomegalovirus cmv infection f hoffmanla roche ltd roche markets tamiflu oseltamivir phosphate treatment influenza royalty paying collaborative agreement us manufacture macugen pegaptamib sodium injection manufacturing agreement osi pharmaceuticals inc osi successor eyetech pharmaceuticals inc sells macugen treatment neovascular agerelated macular degeneration royalty paying collaborative agreement us accompanying consolidated financial statements include accounts company wholly owned subsidiaries joint venture bristol myers squibb company bms gilead primary beneficiary determined financial accounting standards board fasb interpretation consolidation variable interest entities fin r record minority interest consolidated financial statements reflect bmss interest joint venture significant intercompany transactions eliminated certain prior year amounts reclassified consistent current year presentation additionally reclassified million variable rate demand obligations cash cash equivalents availableforsale marketable securities previously reported consolidated balance sheet consolidated statement cash flows included quarterly report form q september reclassification based interpretation cash equivalents pursuant statement financial accounting standards sfas statement cash flows sfas reclassification effect increasing investing cash outflows purchases marketable securities million increasing investing cash inflows sales marketable securities million three nine months ended september stock splits september gilead completed twoforone stock split effected form stock dividend stockholders record august accordingly share per share amounts periods presented reflect stock split significant accounting policies estimates judgments preparation consolidated financial statements requires us make estimates judgments affect reported amounts assets liabilities revenues expenses related disclosures ongoing basis management evaluates estimates including related revenue recognition allowance doubtful accounts inventories prepaid royalties clinical trial accruals tax provision base estimates historical experience various market specific relevant assumptions believed reasonable circumstances results form basis making judgments carrying values assets liabilities readily apparent sources actual results may differ significantly estimates table contents gilead sciences inc notes consolidated financial statementscontinued december revenue recognition recognize revenue product sales persuasive evidence arrangement exists delivery customer occurred price fixed determinable collectibility reasonably assured provide customers general right product return however accept returns product united states expired one year expiration product deemed damaged defective received customer upon recognition revenue product sales provisions made estimated future returns products may expire government reimbursements certain distributor fees customer incentives cash discounts prompt payment estimates government reimbursements cash discounts based contractual terms expectations regarding utilization rates programs estimates distributor fees based contractual terms estimates product returns including new products based ongoing analysis industry historical return patterns well third party data assist us monitoring channel inventory levels subsequent prescriptions contract revenue research development rd recorded performance occurs earnings process completed based performance requirements contract nonrefundable fees performance obligations exist continuing involvement gilead recognized earlier payments received collection reasonably assured revenue nonrefundable upfront license fees milestone payments continue involvement development collaboration obligation supply product recognized performance occurs obligations completed accordance specific terms gileads obligations types arrangements revenue recognized manufacturing obligation fulfilled ratably development manufacturing period revenue associated substantive atrisk milestones recognized based upon achievement milestones defined respective agreements advance payments received excess amounts earned classified deferred revenue royalty revenue sales ambisome recognized month following corresponding sales occur royalty revenue sales products recognized received quarter following quarter corresponding sales occur shipping handling costs shipping handling costs incurred inventory purchases product shipments recorded cost goods sold consolidated statements operations research development expenses major components rd expenses consist personnel costs including salaries benefits clinical studies performed clinical research organizations cros materials supplies licenses fees overhead allocations consisting various administrative facilities related costs rd activities also separated three main categories research clinical development pharmaceutical development research costs typically consist preclinical toxicology costs clinical development costs include costs phase clinical trials pharmaceutical development costs consist expenses incurred product formulation chemical analysis charge rd costs including clinical study costs expense incurred consistent sfas accounting research development costs costs significant component rd table contents gilead sciences inc notes consolidated financial statementscontinued december expenses clinical studies performed third party cros accrue costs clinical studies performed cros straightline basis service periods specified contracts adjust estimates required based upon ongoing review level effort costs actually incurred cro monitor levels performance significant contract including extent patient enrollment activities communications cros adjust estimates required quarterly basis expenses reflect actual effort expended cro material cro contracts terminable us upon written notice gilead generally liable actual effort expended cro point time contract regardless payment status amounts paid advance services performed refunded contract terminated contracts include additional termination payments become due payable gilead terminates contract additional termination payments recorded contract terminated advertising expenses expense costs advertising including promotional expenses incurred advertising expenses million million million earnings loss per share basic earnings loss per share calculated based weightedaverage number common shares outstanding year diluted earnings loss per share calculated based weightedaverage number common shares dilutive securities outstanding dilutive potential common shares resulting assumed exercise outstanding stock options equivalents determined based treasury stock method dilutive potential common shares resulting assumed conversion convertible notes determined based ifconverted method following table reconciliation numerator denominator used calculation basic diluted earnings loss per share thousands year ended december numerator net income loss used calculation basic earnings loss per share interest expense makewhole payment convertible notes redemption net income loss used calculation diluted earnings loss per share denominator weightedaverage common shares outstanding used calculation basic earnings loss per share effect dilutive securities stock options equivalents convertible notes weightedaverage common shares outstanding used calculation diluted earnings loss per share table contents gilead sciences inc notes consolidated financial statementscontinued december options purchase approximately million million shares common stock also outstanding years ended december respectively options included computation diluted earnings per share options exercise prices greater average market price common stock periods therefore effect antidilutive diluted net loss per share excludes prorated effect million convertible subordinated notes would convert approximately million shares effect million convertible senior notes would convert approximately million shares outstanding stock options equivalents purchase million shares effects antidilutive stockbased compensation accordance provisions sfas accounting stockbased compensation amended sfas accounting stockbased compensationtransition disclosure collectively sfas elected continue follow accounting principles board opinion apb accounting stock issued employees fasb interpretation accounting certain transactions involving stock compensationan interpretation apb opinion collectively apb accounting employee stockbased plans apb exercise price gileads employee director stock options equals exceeds fair value underlying stock date grant compensation expense recognized table presents net income loss basic diluted net income loss per share compensation cost gilead nexstar pharmaceuticals inc triangle pharmaceuticals inc triangle stock option plans gilead employee stock purchase plan espp determined based estimated fair value awards plans grant purchase date accordance sfas thousands except per share amounts year ended december net income lossas reported add stockbased employee compensation expense included reported net income loss net related tax effects deduct total stockbased employee compensation expense determined fair value based method awards net related tax effects net income loss used calculation basicpro forma earnings loss per share interest expense makewhole payment convertible debt redemption net income loss used calculation dilutedpro forma earnings loss per share net income loss per share basicas reported basicpro forma dilutedas reported dilutedpro forma table contents gilead sciences inc notes consolidated financial statementscontinued december fair values awards granted stock option plans espp estimated grant purchase dates using blackscholes option valuation model recognized using accelerated expense attribution method refined volatility assumptions used arrive fair value beginning fourth quarter purposes calculating expected volatility rate use time period better reflects current stage development length time public company several drug approvals enabled us achieve positive cash flows operations recent fouryear threeyear periods respectively used purposes calculating expected volatility twoyear time period used derive weighted average volatility fourth quarter weighted average volatility first three quarters refinement assumptions used determine fair value stock options may future generate fair values differ calculated based current model assumptions calculate estimated fair value awards used multiple option approach following assumptions year ended december expected life years stock options vesting date espp purchase date discount rate stock options espp volatility expected dividend yield weighted average estimated fair value espp shares purchased pro forma disclosure presented table currently permitted sfas longer alternative financial statement recognition sfas revised sharebased payment sfas r revision sfas adopted january december fasb issued sfas r supersedes apb amends sfas sfas r requires sharebased payments employees directors including grants stock options recognized income statement based fair values beginning first quarterly period june early adoption permitted sfas r must determine appropriate fair value model related assumptions used valuing sharebased payments amortization method compensation cost transition method used date adoption transition methods include modified prospective retroactive adoption methods modified prospective method requires compensation expense recorded unvested stock options restricted stock beginning first quarter adoption sfas r retroactive methods requires record compensation expense unvested stock options restricted stock beginning first period restated sfas r also requires benefit tax deductions excess recognized compensation cost reported statement cash flows financing cash flow rather operating cash flow required current literature requirement reduce net operating cash flows increase net financing cash flows periods adoption determined adopt modified prospective method continue use blackscholes option valuation model based preliminary analysis expect adoption sfas r table contents gilead sciences inc notes consolidated financial statementscontinued december material impact income statement earnings per share currently estimate impact approximately per share however estimate future sharebased compensation expense affected stock price number stockbased awards board directors may grant well number complex subjective valuation assumptions related tax effect valuation assumptions include limited volatility stock price employee stock option exercise behaviors cash cash equivalents consider highly liquid investments insignificant interest rate risk original maturity three months less purchase date cash equivalents may enter overnight repurchase agreements repos purchase securities obligation resell following day securities purchased agreements resell recorded face value reported cash cash equivalents investment policy may enter repos major banks authorized dealers provided repos collateralized us government securities fair value least fair value securities sold gilead eligible instruments investment policy included cash equivalents include commercial paper money market funds bank obligations marketable nonmarketable securities determine appropriate classification marketable securities consist solely debt securities include auction rate securities variable rate demand obligations time purchase reevaluate designation balance sheet date marketable securities considered availableforsale carried estimated fair values reported either cash equivalents marketable securities unrealized gains losses availablefor sale securities excluded earnings reported separate component stockholders equity interest income net includes interest dividends amortization purchase premiums discounts realized gains losses sales securities cost securities sold based specific identification method regularly review investments otherthantemporary declines fair value review includes consideration cause impairment including creditworthiness security issuers number securities unrealized loss position well severity duration unrealized losses determine decline fair value investment accounting basis otherthantemporary reduce carrying value securities hold record loss amount decline reductions required past three years result entering collaborations time time gilead may hold investments nonpublic companies record nonmarketable securities cost noncurrent assets less amounts otherthantemporary impairment regularly review investments indicators impairment investments nonmarketable securities material periods presented concentrations risk subject credit risk portfolio cash equivalents marketable securities policy limit amounts invested securities duration industry group investment type issuer except securities issued us government exposed significant concentrations credit risk financial instruments goals investment policy order priority follows safety preservation principal diversification risk liquidity investments sufficient meet cash flow requirements competitive aftertax rate return table contents gilead sciences inc notes consolidated financial statementscontinued december also subject credit risk accounts receivable related product sales significant amount trade accounts receivable arises product sales united states europe certain countries payments typically slow primarily greece italy portugal spain accounts receivable balances significant cases slow payment practices reflect pace governmental entities reimburse customers turn may increase financial risk related certain customers sales customers countries tend relatively slow paying past increased future may increase average length time accounts receivable outstanding december past due accounts receivable greece italy portugal spain totaled million million days past due based contractual terms receivables december past due receivables countries million million days past due date experienced significant losses respect collection accounts receivable believe past due accounts receivable net allowances reflected consolidated balance sheet collectible perform credit evaluations customers financial condition generally required collateral certain materials utilize operations obtained one supplier many materials utilize operations made one facility since suppliers key components materials must named new drug application nda filed us food drug administration fda product significant delays occur qualification new supplier required delivery material suppliers interrupted reason may unable ship viread ambisome hepsera emtriva truvada vistide supply products development clinical trials accounts receivable trade accounts receivable recorded net allowances cash discounts prompt payment doubtful accounts government chargebacks sales returns estimates cash discounts government chargebacks sales returns based contractual terms historical trends expectations regarding utilization rates programs estimates allowance doubtful accounts determined based existing contractual obligations historical payment patterns customers individual customer circumstances analysis days sales outstanding customer geographic region review local economic environment potential impact government funding reimbursement practices historically amounts uncollectible accounts receivable written insignificant consistent managements expectations inventories inventories recorded lower cost market cost determined firstin firstout basis periodically review composition inventory order identify obsolete slowmoving otherwise unsaleable items unsaleable items observed alternate uses inventory record writedown net realizable value period impairment first recognized historically inventory writedowns insignificant consistent managements expectations prepaid royalties prepaid royalties recorded cost based present value future royalty obligation would expect pay expected levels product sales incorporating related technology review prepaid royalties least annually indicators would support writedown net recoverable value table contents gilead sciences inc notes consolidated financial statementscontinued december assets amortize prepaid royalties cost goods sold remaining life underlying patent based effective royalty rate derived forecasted future product sales incorporating related technology review effective royalty rate least annually prospectively adjust effective rate based significant new facts circumstances may arise review property plant equipment property plant equipment stated cost less accumulated depreciation amortization depreciation amortization recognized using straightline method land depreciated repairs maintenance costs expensed incurred estimated useful lives years follows description estimated useful life buildings improvements laboratory manufacturing equipment office computer equipment leasehold improvements life related lease office computer equipment includes capitalized computer software capitalized software purchased internally developed computer software leasehold improvements capitalized leased equipment amortized shorter lease term assets useful life amortization capitalized leased equipment included depreciation expense capitalized interest construction progress included property plant equipment interest capitalized interest capitalized insignificant intangible assets intangible assets definite lives amortized estimated useful lives reviewed impairment facts circumstances suggest carrying value assets may recoverable inplace lease intangible asset amortized related lease term discussed note impairment longlived assets carrying value longlived assets reviewed regular basis existence facts circumstances internally externally may suggest impairment specific potential indicators impairment include significant decrease fair value asset significant change extent manner asset used significant physical change asset significant adverse change legal factors business climate affects value asset adverse action assessment fda another regulator accumulation costs significantly excess amount originally expected acquire construct asset operating cash flow losses combined history operating cash flow losses projection forecast demonstrates continuing losses associated incomeproducing asset indication impairment test recoverability comparing estimated undiscounted future cash flows expected result use asset eventual disposition carrying amount asset estimating future cash flows assets liabilities grouped lowest level identifiable cash flows largely independent cash flows generated groups undiscounted future cash flows less carrying amount asset impairment loss measured excess carrying value asset estimated fair value recognized cash flow estimates used calculations based managements best estimates using appropriate customary assumptions projections time table contents gilead sciences inc notes consolidated financial statementscontinued december foreign currency translation transactions contracts adjustments resulting translating financial statements foreign subsidiaries us dollars excluded determination net income loss accumulated separate component stockholders equity net foreign exchange transaction gains losses reported selling general administrative sga expenses consolidated statements operations realized gains losses million million million hedge certain foreign currency exposures related outstanding trade accounts receivable forecasted product sales foreign exchange forward contracts general market risks contracts offset corresponding gains losses transactions hedged exposure credit risk contracts function changes interest currency exchange rates therefore varies time gilead limits risk counterparties contracts may unable perform transacting major banks also limit risk loss entering contracts provide net settlement maturity therefore overall risk loss event counterparty default limited amount unrecognized unrealized gains outstanding contracts ie contracts positive fair value date default enter speculative foreign currency transactions write options presently hedge net investment foreign subsidiaries accounting hedges net monetary assets liabilities record changes fair value sga expenses derivative instruments designated hedges sfas nos accounting derivative instruments hedging activities collectively referred sfas selectively hedge anticipated currency exposures purchasing forward contracts hedge anticipated product sales next year less designated cash flow hedges sfas unrealized gains losses underlying forward contracts recorded comprehensive income loss recognized earnings forecasted transaction occurs december december net unrealized gains losses million million respectively open foreign exchange forward contracts gains losses cash flow hedges recorded product sales increased decreased product sales million million million respectively notional amounts forward exchange contracts outstanding million december million december asset fair value million liability fair value million december respectively contracts maturities one year less see note discussion derivative financial instruments fair value financial instruments financial instruments consist principally cash cash equivalents marketable securities accounts receivable certain noncurrent assets forward foreign exchange contracts accounts payable longterm debt longterm obligations cash cash equivalents marketable securities see note forward foreign exchange contracts hedge accounts receivable see note reported respective fair values balance sheet forward foreign exchange contracts hedge forecasted sales recorded fair value net related deferred gain loss resulting reported net balance zero gilead called convertible senior notes redemption october converted shares gilead common stock november believe remaining financial instruments reported consolidated balance sheet amounts approximate current fair values table contents gilead sciences inc notes consolidated financial statementscontinued december income taxes income tax provision computed liability method deferred tax assets liabilities determined based difference financial statement tax basis assets liabilities using enacted tax rates effect year differences expected reverse significant estimates required determining provision income tax estimates based interpretations existing tax laws regulations believe estimates reasonable reserves income tax related uncertainties adequate various internal external factors may favorable unfavorable effects future effective income tax rate factors include limited changes tax laws regulations andor rates changing interpretations existing tax laws regulations changes international organization changes overall levels income tax derivative financial instruments derivatives recognized either assets liabilities measured fair value enter foreign currency forward contracts hedge changes fair value significant monetary assets liabilities denominated nonfunctional currency derivative designated meets definition fair value hedge changes fair value derivative hedged item recognized earnings enter foreign currency forward contracts generally maturities months less hedge future cash flows related forecasted product sales foreign denominated currencies derivative instruments employed eliminate minimize certain foreign currency exposures confidently identified quantified hedges related forecasted foreign currency product sales designated documented inception respective hedge designated cash flow hedges evaluated effectiveness monthly terms forward contract underlying transaction matched inception forward contract effectiveness calculated comparing fair value contract estimated change fair value underlying hedged item effective component hedge recorded accumulated comprehensive income loss see note substantially values reported accumulated comprehensive income december reclassified earnings within months residual changes fair value instruments including resulting cancellation dedesignation hedge contracts ineffectiveness recognized immediately sga expense impact ineffectiveness significant consolidated statements operations gains losses million million million hedging contracts recognized consolidated statements operations respectively result entering collaboration arrangement gilead held warrants purchase stock nonpublic company completed initial public offering january see notes warrants exercised end first quarter acquisition triangle pharmaceuticals inc january completed acquisition net assets triangle expand antiviral pipeline triangle development stage company particular focus potential therapies human immunodeficiency virus hiv including aids hepatitis b virus hbv triangles portfolio consisted several drug candidates clinical trials including emtricitabine treatment hiv infection emtricitabine treatment chronic hepatitis b amdoxovir treatment hiv infection clevudine treatment chronic hepatitis b july fda granted marketing approval emtriva table contents gilead sciences inc notes consolidated financial statementscontinued december treatment hiv october european commission granted marketing authorisation emtriva fifteen member states european union triangle acquisition accounted acquisition assets rather business combination accordance criteria outlined emerging issues task force triangle development stage company commenced planned principal operations lacked necessary elements business completed products therefore ability access customers results operations triangle since january included consolidated financial statements primarily consist rd expenses lesser extent sga expenses december part arrangements contemplated proposed acquisition triangle gilead million loan extended triangle working capital corporate purposes triangle issued gilead unsecured convertible promissory note upon completion acquisition january loan eliminated consolidated financial statements aggregate purchase price million including cash paid million outstanding stock fair value stock options assumed million direct transaction costs million employee related costs million part purchase established workforce reduction plan also assumed obligations various change control agreements acquisition date million employee termination costs change control obligations recorded liability paid period approximately two years december employee termination costs change control obligations fully paid following table summarizes purchase price allocation january thousands net tangible assets assembled workforce deferred compensation inprocess rd million net tangible assets includes assumed liabilities million million value assigned assembled workforce amortized three years estimated useful life asset deferred compensation represents intrinsic value unvested stock options assumed transaction december amortized remaining vesting period options extends january table contents gilead sciences inc notes consolidated financial statementscontinued december upon reversal deferred tax asset valuation allowance fourth quarter remaining million assembled workforce asset eliminated see note approximately million purchase price allocated purchased inprocess rd represented fair value triangles incomplete rd programs yet reached technological feasibility alternative future use acquisition date summary programs acquisition date follows updated subsequent changes status development estimated acquisition date fair value program description status development millions emtricitabine hiv nucleoside analogue four phase studies completed prior shown inhibitor hiv acquisition date us marketing approval received replication patients fda july emtriva european union approval received european commission october emtricitabinetenofovir df fixed fixeddose coformulation tenofovir acquisition date work dose combination hiv therapy emtricitabine commenced potential coformulation except extent work emtricitabine single agent progressing march applications marketing approval submitted united states european union august marketing approval united states received fda truvada fixeddose coformulation tenofovir emtricitabine marketing approval european union received february sales commenced later first quarter amdoxovir hiv purine dioxolane nucleoside may program phase trials acquisition offer advantages marketed date terminated licensing agreement nucleosides activity emory university georgia research drug resistant viruses exhibited foundation inc development patients hiv infection discontinued clevudine hbv pyrimidine nucleoside analogue program phase trials acquisition shown inhibitor hbv date august licensing agreement replication patients chronically infected bukwang pharm ind co ltd terminated hbv development discontinued table contents gilead sciences inc notes consolidated financial statementscontinued december estimated acquisition date fair value program description status development millions emtricitabine hbv inhibitor hbv replication program phase trials acquisition patients chronically infected hbv date completed december continue evaluate strategy development emtricitabine hepatitis b indication currently expect undertake significant rd activities next several years value purchased inprocess rd determined estimating related future net cash flows using present value risk adjusted discount rate discount rate significant assumption based estimated weighted average cost capital adjusted upward risks associated projects acquired projected cash flows acquired projects based estimates revenues operating profits related projects considering stage development potential product acquired time resources needed complete development approval product life potential commercialized product associated risks including inherent difficulties uncertainties developing drug compound including obtaining fda regulatory approvals risks related viability potential alternative treatments future target markets acquisition real estate september completed purchase foster city california campus million cash purchase included buildings totaling square feet office laboratory space accordance sfas business combinations sfas goodwill intangible assets purchase price allocated land buildings existing inplace leases based estimated relative fair values land buildings recorded million million respectively fair value buildings depreciated remaining economic life estimated years used market approach value existing leases acquired recorded intangible asset approximately million amortized straightline basis net rental income approximately two years remaining term leases accumulated amortization intangible asset million million december december respectively amortization expense million million million respectively net rental income generate leases amortization intangible asset included interest income net approximately million million leases terminated november asset impairment fourth quarter recorded asset impairment charge million certain longlived assets primarily leasehold improvements manufacturing laboratory equipment classified held use noncash charge driven decision terminate liposomal rd activities san dimas discontinue daunoxome daunorubicin citrate liposome injection product line impairment based analysis undiscounted cash flows generated affected assets compared carrying value carrying value exceeded related estimated undiscounted cash flows wrote carrying value longlived assets estimated fair value accordance table contents gilead sciences inc notes consolidated financial statementscontinued december sfas accounting impairment disposal longlived assets sfas estimated fair value derived using expected cash flow approach subsequent decision discontinue daunoxome product line received unanticipated requests europe asking gilead reconsider selling daunoxome result requests management decided continue selling product certain countries although evaluating supply sales strategy respect daunoxome accordance sfas write assets continue used daunoxome product line established new cost basis assets adjusted new facts circumstances gain warrant march entered agreement eyetech pharmaceuticals inc eyetech predecessor osi pharmaceuticals inc relating proprietary aptamer eye currently known macugen pursuant agreement received warrant purchase shares eyetech series b convertible preferred stock exercisable price per share january eyetech completed initial public offering common stock time adjusted carrying value warrant estimated fair value resulting gain million included consolidated statement operations year ended december fair value warrant estimated using blackscholes valuation model volatility rate discount rate end first quarter exercised warrant net basis using shares eyetech common stock consideration exercise price subsequently held shares eyetech common stock second quarter sold eyetech shares held realized gain million included interest income net consolidated statement operations year ended december availableforsale securities following summary availableforsale securities recorded cash equivalents marketable securities consolidated balance sheets estimated fair values availableforsale securities based prices obtained commercial pricing services thousands gross gross amortized unrealized unrealized estimated cost gains losses fair value december us treasury securities obligations us government agencies corporate debt securities assetbacked securities municipal debt securities debt securities total december us treasury securities obligations us government agencies corporate debt securities assetbacked securities municipal debt securities debt securities total table contents gilead sciences inc notes consolidated financial statementscontinued december december debt securities consist primarily money market funds auction rate securities december debt securities consist primarily money market funds availableforsale securities included cash equivalents million million december respectively december portfolio availableforsale securities excludes million assetbacked securities comprised million securities contractual maturity less one year million securities contractual maturity greater one year less five years auction rate securities variable rate demand obligations aggregate fair value million contractual maturities greater ten years contain dutch auction put features less days none estimated maturities assetbacked securities exceeded five years following table presents certain information related sales availableforsale securities thousands year ended december proceeds sales gross realized gains sales gross realized losses sales december following availableforsale securities continuous unrealized loss position deemed thantemporarily impaired thousands less months months greater gross gross unrealized estimated unrealized estimated losses fair value losses fair value december us treasury securities obligations us government agencies corporate debt securities assetbacked securities municipal debt securities debt securities total december us treasury securities obligations us government agencies corporate debt securities assetbacked securities municipal debt securities debt securities total table contents gilead sciences inc notes consolidated financial statementscontinued december gross unrealized losses caused interest rate increases significant facts circumstances arisen indicate deterioration creditworthiness issuers securities based review securities including assessment duration severity related unrealized losses recorded otherthantemporary impairments securities european headquarters relocation june gilead announced commercial medical administrative groups european headquarters based paris france would relocated london area united kingdom european headquarters regulatory safety information technology groups currently located cambridge area united kingdom believe relocation enable us achieve efficiencies closer proximity groups gilead positions compete large pharmaceutical companies global level gileads french subsidiary continue occupy gileads existing french facilities continue maintain expand sales marketing presence france third quarter relocation plans finalized gilead accrued charge million primarily consisting employee severance costs termination benefits included sga expenses consolidated statement operations december approximately million charged accrual included accrued compensation employee benefits consolidated balance sheet remaining payments expected made first half additional costs relating new headquarters united kingdom including recruitment costs legal expenses capital expenditures related costs recorded incurred based upon current information available believe aggregate severance relocation recruiting costs resulting european headquarters relocation range million million table contents gilead sciences inc notes consolidated financial statementscontinued december consolidated balance sheet detail thousands december inventories raw materials work process finished goods total property plant equipment net buildings improvements including leasehold improvements laboratory manufacturing equipment office computer equipment capitalized leased equipment construction inprogress less accumulated depreciation amortization including relating capitalized leased equipment respectively subtotal land total accrued compensation employee benefits accrued bonuses accrued compensation employee benefits total accrued liabilities accrued medicaid rebates fair value forward foreign currency contracts value added taxes payable accrued royalty expenses liabilities total joint venture bristolmyers squibb december entered collaboration bristolmyers squibb company bms develop commercialize fixeddose combination gileads truvada bmss sustiva efavirenz united states structured joint venture gilead bms formed limited liability company bristol myers squibb gilead sciences llc terms collaboration gilead bms granted royaltyfree sublicenses joint venture use respective companyowned technologies return granted license joint venture use intellectual property results collaboration ownership interests joint venture gilead bms reflect respective economic interests based fraction estimated net selling price fixeddose combination product attributable table contents gilead sciences inc notes consolidated financial statementscontinued december truvada sustiva respectively adjusted annual basis since net selling price truvada may change time relative net selling price sustiva gileads bmss respective economic interests joint venture may vary annually gilead primary responsibility clinical development activities regulatory filings relating new products resulting collaboration bms gilead share marketing sales efforts parties provide equivalent sales force efforts minimum number years daily operations joint venture governed four primary joint committees gilead responsible accounting financial reporting product distribution joint venture parties agreed provide respective bulk active pharmaceutical ingredients joint venture estimated net selling price december joint venture held approximately million sustiva active pharmaceutical ingredient purchased bms bmss estimated net selling price sustiva us market joint ventures total equity investment risk expected sufficient allow finance operational activities without ongoing funding gilead bms although primary beneficiary legal structure joint venture limits recourse creditors general credit assets gilead explained note consolidated financial statements include results joint venture bms reflect bmss interest joint venture minority interest collaborative arrangements contracts roche september gilead entered development license agreement agreement f hoffmannla roche ltd hoffmannla roche inc together roche develop commercialize therapies treat prevent viral influenza tamiflu antiviral oral formulation treatment prevention influenza codeveloped company roche agreement roche exclusive right manufacture sell tamiflu worldwide subject obligation pay gilead percentage net revenues roche generates tamiflu sales turn subject reduction certain defined manufacturing costs june gilead delivered notice termination roche material breach agreement november gilead resolved dispute roche relating breach agreement agreed terminate related arbitration pending parties connection dispute resolution gilead roche entered first amendment supplement agreement amended agreement provides formation joint manufacturing committee review roches existing manufacturing capacity tamiflu global plans manufacturing tamiflu us commercial committee evaluate commercial plans strategies tamiflu united states joint supervisory committee evaluate roches overall commercial plans tamiflu global basis case consisting representatives gilead roche amended agreement also option provide specialized sales force supplement roches marketing efforts united states tamiflu royalties payable gilead net sales tamiflu sold roche remain amended agreement follows percent first million worldwide net sales given calendar year b percent next million worldwide net sales calendar year c percent worldwide net sales excess million calendar year amended agreement revises provision agreement relating calculation royalty payments given calendar quarter roche pay us royalties based actual royalty rates applicable quarter addition royalties payable roche us longer subject cost goods sold table contents gilead sciences inc notes consolidated financial statementscontinued december adjustment provided agreement roche paid gilead million gilead recognized royalty revenues consisting million relating disputed royalties million relating reimbursement cost goods adjustment million relating updating royalties payable gilead first nine months based current year royalty rates instead prior years effective royalty rate recorded total million million million tamiflu royalties respectively recognize royalty revenue roche quarter following quarter related tamiflu sales occur recognized contract revenue million milestone payment japanese approval tamiflu prophylaxis last milestones receivable agreement emory university july gilead royalty pharma purchased royalty interest owned emory university emory emtricitabine terms agreement gilead royalty pharma paid respectively total purchase price million emory exchange elimination emtricitabine royalties due emory worldwide net sales product containing emtricitabine result transaction capitalized prepaid royalties share million purchase price million begun amortize prepaid royalty cost goods sold remaining life underlying patent based effective royalty rate derived forecasted future product sales amortization amount million record royalties royalty pharma based actual emtricitabine net sales relative royalty pharmas ownership underlying emory royalty interest paid royalties million royalty pharma july gilead made payment million emory connection amendment restatement existing license agreement emory providing gilead greater strategic flexibility development emtricitabine hepatitis b indication recorded payment rd expenses currently expecting significant related rd next several years prior july paid royalties emory respect emtricitabine hiv indication worldwide license acquired acquisition triangle paid royalties million million million respectively net sales emtriva net sales truvada also incorporates emtricitabine technology launched iocbrega gilead entered agreements institute organic chemistry biochemistry academy sciences czech republic rega stichting iocbrega relating certain nucleotide compounds discovered two institutions agreements gilead received exclusive right manufacture use sell nucleotide compounds gilead obligated pay iocbrega percentage net revenues received sales products containing compounds subject minimum royalty payments products covered agreement include vistide hepsera viread august agreements iocbrega amended include truvada future fixeddose combination products contain licensed technology gilead currently makes quarterly payments iocbrega based percentage vistide hepsera viread truvada net sales paid royalties million million million iocbrega respectively december agreements iocbrega amended provide reduced royalty rate future sales tenofovir adefovir return upfront payment gilead million upon table contents gilead sciences inc notes consolidated financial statementscontinued december signing agreement payment recorded longterm prepaid royalty classified assets balance sheet december prepaid royalty recognized royalty expense expected commercial life tenofovir adefovir amortization million payment began product launch dates viread hepsera japan tobacco march entered licensing agreement japan tobacco inc japan tobacco japan tobacco granted gilead exclusive rights develop commercialize novel hiv integrase inhibitor gs also known jtk countries world excluding japan japan tobacco retain rights terms agreement gilead incurred upfront license fee million included rd expenses first quarter technology incomplete future alternative use technology additionally obligated make payments japan tobacco upon achievement certain milestones pay royalties based future net product sales territories may market drug july gilead entered licensing agreement japan tobacco japan tobacco would commercialize products hiv product portfolio japan agreement includes viread truvada emtriva terms agreement received upfront license fee million entitled receive additional payments upon achievement certain milestones japan tobacco pays us royalty net sales products japan upfront fee recorded deferred revenue amortized contract revenue period supply products japan tobacco approximately years december received million year milestone payments japan tobacco related japanese regulatory approval marketing authorization viread amortizing remaining period upfront license fee january japan tobacco submitted marketing authorization applications emtriva truvada japanese regulatory authorities march emtriva truvada approved sale japan achillion pharmaceuticals november entered exclusive license collaboration agreement achillion pharmaceuticals inc achillion agreement granted worldwide rights research development commercialization certain small molecule hcv replication inhibitors involving hcv protease treatment infection hepatitis c virus hcv collaboration achillion obligated continue development compounds according mutually agreed upon development plan completion proofofconcept clinical study hcvinfected patients costs incurred achieve proofof concept shared equally gilead achillion costs incurred amounted million following proofofconcept study gilead obligated assume full responsibilities incur costs associated development commercialization compounds warranting development achillion option participate us commercialization efforts future products arising collaboration conjunction signing collaboration gilead paid million upfront license fee recorded rd expense future alternative use licensed technology additionally invested achillions convertible preferred stock agreed make payments achillion upon achievement certain milestones outlined agreement pay royalties future net sales products arising collaboration gilead achillion began dosing patients phase study gs also known ach treatment hepatitis c december net investment achillions nonmarketable convertible preferred stock million recorded noncurrent assets table contents gilead sciences inc notes consolidated financial statementscontinued december genelabs technologies september entered license research collaboration agreement genelabs technologies inc genelabs research develop commercialize certain genelabs novel nucleoside inhibitors hcv polymerase treatment chronic infection caused hcv conjunction signing collaboration agreement paid million upfront license fee recorded rd expense future alternative use technology initially agreed upon term three years genelabs obligated lead research efforts gilead option extend research term collaboration additional year gilead lead development commercialization activities agreed provide annual funding full time equivalents made million payments genelabs recorded rd expense obligated make additional payments upon achievement certain milestones pay royalties future net sales selected compounds developed approved relation collaboration medarex inc july entered agreement medarex inc medarex medarex would buyout future royalty obligations us approved products result medarexs licensing patent estate previously held nexstar inc total amount due us agreement million scheduled paid eight installments either cash medarex stock medarexs option received two installments totaling million four installments totaling million recorded contract revenue chiron corporation august entered nonexclusive licensing agreement chiron corporation chiron research development commercialization small molecule therapeutics selected hcv drug targets agreement gilead received nonexclusive rights use chirons hcv technology develop commercialize products treatment hcv terms agreement paid chiron upfront license fee million recorded rd expense future alternative use licensed technology also agreed make additional payments chiron certain clinical regulatory contractually determined milestones met made million payments chiron recorded rd expense additionally obligated make royalty payments event product developed using licensed technology glaxosmithkline april gilead gsk entered licensing agreement providing gsk rights commercialize hepsera oral antiviral treatment chronic hepatitis b asia latin america certain territories agreement retained rights hepsera united states canada eastern western europe australia new zealand turkey gsk received exclusive rights develop hepsera solely treatment chronic hepatitis b territories significant include china japan korea taiwan addition received million milestone payment gsk us approval hepsera million canadian approval hepsera aggregate million commercial approvals hepsera japan south korea taiwan gsk full responsibility development commercialization hepsera territories upfront license fee approval milestones recorded deferred revenue total million million million recognized contract revenue respectively million balance table contents gilead sciences inc notes consolidated financial statementscontinued december deferred revenue december expected amortized contract revenue period supply hepsera gsk agreement approximately years addition gsk required pay gilead royalties net product sales gsk generates sales hepsera epivirhbvzeffix gsks hepatitis product gsk territories gilead began receiving royalties gsks sales hepsera first quarter recorded million million royalty revenue respectively recognize royalty revenue gsk quarter following quarter related hepsera sales occur eyetech pharmaceuticals inc predecessor osi march entered agreement eyetech pharmaceuticals inc eyetech predecessor osi relating macugen macugen inhibitor vascular endothelial growth factor vegf known play role development certain ophthalmic diseases terms agreement eyetech received worldwide rights therapeutic uses macugen responsible rd costs entitled payments eyetech eyetech reaches certain macugen milestones well royalties worldwide net sales macugen also required make payments third parties relating royalties february macugen approved european union entitled receive million milestone payment first commercial sale made december entered agreement eyetech supply macugen eyetech three years recorded contract revenue million million million respectively connection clinical supplies provided eyetech milestones achieved eyetech recognized contact revenue million milestone payments eyetech second third quarters upon filing new drug applications europe united states macugen january eyetech received fda approval sale macugen united states agreement eyetech expires upon later ten years first commercial sale product developed date last patent expires agreement additionally received warrant purchase shares eyetech series b convertible preferred stock exercisable price per share price stock issued investors see note discussion warrant eventual sale eyetech shares astellas pharma inc rights market ambisome subject agreement gilead astellas pharma inc astellas successor fujisawa usa inc terms astellas agreement amended astellas sole marketing rights ambisome canada exclusive marketing rights ambisome rest world provided pay royalties astellas connection sales significant markets asia including china india japan korea taiwan connection us sales astellas purchases ambisome gilead manufacturing cost sales canada astellas purchases ambisome manufacturing cost plus specified percentage astellas collects payments sale ambisome united states canada receive royalties equal astellas gross profits sale ambisome united states canada gross profits include deduction cost goods sold giving us current effective royalty rate approximately astellas net sales ambisome united states connection agreement recorded royalty revenue million million million table contents gilead sciences inc notes consolidated financial statementscontinued december longterm obligations total longterm obligations consist following thousands december capital lease obligations monthly installments interest rates ranging longterm loan quarterly installments interest rates libor plus tiered contractual rate total longterm obligations less current portion total longterm obligations due one year future minimum payments longterm obligations follows thousands capital lease longterm year ending december obligations loan total less amount representing interest total terms various debt agreements require us comply certain financial operating covenants december compliance covenants credit facilities december entered agreement syndicate banks provide fiveyear million senior credit facility million facility consisted uncollateralized million term loan entered gilead biopharmaceutics ireland corporation gbic whollyowned irish subsidiary gilead uncollateralized million revolving credit facility entered us parent company gilead sciences inc proceeds term loan used gbic december facilitate cash dividend distribution million parent company part repatriation qualified foreign earnings provisions american jobs creation act ajca terms million term loan minimum principal payments repaid end calendar quarter beginning march million interest accrued rate libor plus tiered contractual rate basis points payable arrears end quarter gbic prepay term loan time whole part together accrued interest prepaid principal table contents gilead sciences inc notes consolidated financial statementscontinued december without penalty premium outstanding interest principal december payable demand december million outstanding term loan agreement us parent company another whollyowned subsidiary gilead vintage park llc guarantors terms million revolving credit facility interest accrued payable rate libor plus tiered contractual rate basis points payable arrears end quarter parent company prepay outstanding borrowings time whole part together accrued interest prepaid principal without penalty premium outstanding interest principal december payable demand capacity revolving credit facility increase maximum million million term loan repaid ability irrevocably cancel unutilized portion revolving credit facility whole part proceeds obtained revolving credit facility expected used working capital capital expenditures general corporate purposes including issuance letters credit million december borrowings revolving credit facility whollyowned subsidiary gilead gilead vintage park llc guarantor convertible senior notes december gilead issued million convertible senior notes due december notes convertible total shares gilead common stock per share convertible senior notes provisionally redeemable whole part option gilead time june specified redemption prices plus accrued interest debt issuance costs million incurred connection issuance notes recorded noncurrent assets amortized interest expense straightline basis contractual term notes gilead called convertible senior notes redemption october issued shares gilead common stock note holders upon conversion november redemption price equal principal amount notes redeemed plus accrued unpaid interest redemption date connection redemption gilead paid makewhole payment million note holders representing equivalent per principal value notes less interest actually paid accrued unpaid date issuance notes redemption date upon conversion million unamortized balance related debt issuance costs reclassified additional paidin capital convertible subordinated notes december gilead issued million convertible subordinated notes due december convertible subordinated notes convertible total shares gilead common stock per share convertible subordinated notes redeemable whole part option gilead time december specified redemption prices plus accrued interest debt issuance costs million incurred connection issuance convertible subordinated notes recorded noncurrent assets amortized interest expense straightline basis contractual term convertible subordinated notes november gilead called convertible subordinated notes redemption converted notes shares common stock december upon conversion million unamortized balance related debt issuance costs reclassified additional paidin capital table contents gilead sciences inc notes consolidated financial statementscontinued december commitments contingencies lease arrangements entered various longterm noncancelable operating leases equipment facilities facility leases foster city san dimas california durham north carolina dublin area ireland london area united kingdom expire various dates foster city lease two fiveyear renewal options durham lease two sevenyear renewal options leases ireland united kingdom years respectively rent subject increase fifth anniversary commencement dates also operating leases sales marketing administrative facilities europe canada australia various terms equipment leases include two corporate aircrafts varying terms one provides us renewal option upon expiration lease term lease expense operating leases totaled approximately million million million aggregate noncancelable future minimum rental payments operating leases follows thousands years ending december operating leases thereafter legal proceedings number states counties municipalities filed complaints alleging large number pharmaceutical defendants including instances gilead reported inaccurate prices products causing governmental entity named plaintiff overpay pharmaceutical products furnished participants medicaid program twentysix separate actions filed new york city numerous new york counties consolidated multidistrict litigation proceeding united states district court district massachusetts august cases voluntarily dismissed respect gilead knowledge gilead named three additional cases state alabama v abbott laboratories inc et al currently pending circuit court montgomery county alabama county erie v abbott laboratories inc et al currently pending united states district court district massachusetts state mississippi v abbott laboratories inc et al currently pending chancery court first judicial district hinds county mississippi complaints assert claims federal state law seek damages state alabama case treble damages attorneys fees intend defend cases vigorously cases preliminary stage possible predict outcome amounts accrued related outcome cases purported class action complaint filed november united states district court northern district california gilead companys chief executive officer chief financial officer former executive vice president operations current senior business advisor executive vice table contents gilead sciences inc notes consolidated financial statementscontinued december president research development senior vice president manufacturing senior vice president research complaint alleges defendants violated federal securities laws specifically sections b securities exchange act amended rule b securities exchange commission making certain alleged false misleading statements plaintiffs seek unspecified damages behalf purported class purchasers gileads securities period july october similar actions subsequently filed court issued order consolidating lawsuits single action december february court issued order appointing lead plaintiffs consolidated action april lead plaintiffs behalf purported class filed consolidated amended complaint june company individual defendants filed motion dismiss consolidated amended complaint january court granted defendants motion dismiss leave amend plaintiffs filed second amended complaint february third amended complaint march october court granted defendants notion dismiss third amended complaint leave amend december plaintiffs filed fourth consolidated amended complaint court heard defendants motion dismiss february took matter submission yet rendered decision intend defend cases vigorously outcome predicted time amount accrued related outcome matter also party various legal actions arose ordinary course business believe legal actions material adverse impact business results operations financial position commitments contingencies normal course business may subject contingencies may arise matters product liability claims legal proceedings shareholder suits tax matters accrue contingencies accordance sfas accounting contingencies normal course business entered various firm purchase commitments active pharmaceutical ingredients inventoryrelated items december approximately million purchase commitments follows million million million stockholders equity preferred stock gilead shares authorized preferred stock issuable series board directors board authorized determine designation powers preferences rights series reserved shares preferred stock potential issuance amended restated rights agreement entered gilead preferred stock outstanding december employee stock purchase plan gileads employee stock purchase plan espp employees purchase shares gilead common stock based percentage compensation purchase price per share must equal least lower market value date offered date purchased total shares common stock reserved issuance espp december shares total shares reserved issued espp shares december table contents gilead sciences inc notes consolidated financial statementscontinued december stock option plans may gileads stockholders approved gilead adopted equity incentive plan plan replacement stock option plan plan nonemployee directors stock option plan directors plan plan shares plus shares previously authorized available issuance plan directors plan reserved issuance may gileads stockholder approved increase additional shares common stock available issuance plan plan provides issuance various types equity awards incentive stock options nonstatutory stock options stock appreciation rights sar dividend equivalent rights restricted stock performance units performance shares phantom shares plan exercise purchase price incentive stock options nonstatutory stock options sars shall less fair value gileads common stock date grant case types awards exercise purchase price determined plan administrator incentive stock options typically vest five years pursuant formula determined board expire ten years term awards shall term stated award agreement ten years date grant eligible participants include employees directors consultants gilead except employees eligible incentive stock options compensation committee delegate determines awards granted well vesting terms december shares remaining available future grant plan november gilead adopted plan issuance common stock employees consultants options issued plan discretion board either incentive stock options nonqualified stock options may plan amended exercise price stock options must least equal fair value gileads common stock date grant options vest five years pursuant formula determined board expire ten years plan amended restated april extend term plan may stockholders approved amendment plan increased total number authorized shares plan may remaining shares available future grant plan transferred plan additionally options granted plan expire otherwise terminate without exercised shares common stock reserved options become available future grant plan november gilead adopted directors plan issuance common stock nonemployee directors pursuant predetermined formula exercise price options granted directors plan must least equal fair value gileads common stock date grant options granted january vesting five years date grant quarterly five percent installments initial options granted january january new directors vest three years date grant equal annual installments annual grants existing directors vest one year initial options granted january new directors vest two years date grant equal installments annual grants existing directors vest immediately options expire ten years may stockholders approved amendment directors plan increased total number authorized shares plan may remaining shares available grant plan transferred plan additionally options granted plan expire otherwise terminate without exercised shares common stock reserved options become available future grant plan stock plans assumed gilead merger nexstar include stock option plan incentive stock plan director option plan collectively nexstar plans options pursuant table contents gilead sciences inc notes consolidated financial statementscontinued december nexstar plans issued outstanding july converted options purchase gilead common stock result merger remain subject original terms conditions shares available grant future options nexstar plans stock plans assumed gilead acquisition net assets triangle include stock option plan separate stock option agreement former chief executive officer triangle collectively triangle plans options pursuant plan issued outstanding january converted options purchase approximately million shares gilead common stock result acquisition remain subject original terms conditions shares available grant future options triangle plans following table summarizes activity gilead nexstar triangle stock option plans option grants presented table exercise prices less fair value underlying stock grant date shares thousands year ended december weighted weighted weighted average average average exercise exercise exercise shares price shares price shares price outstanding beginning year granted assumed forfeited exercised outstanding end year exercisable end year weighted average fair value options granted following summary gilead options outstanding options exercisable december options thousands options outstanding options exercisable weighted average weighted remaining average weighted options contractual exercise options average exercise range exercise prices outstanding life years price exercisable price total rights agreement november entered rights agreement rights plan rights plan provides distribution preferred stock purchase right dividend share gilead common stock table contents gilead sciences inc notes consolidated financial statementscontinued december purchase rights currently exercisable certain conditions involving acquisition proposed acquisition person group common stock purchase rights permit holders holder purchase gilead common stock discount market price time upon payment specified exercise price per purchase right addition event certain business combinations purchase rights permit purchase common stock acquirer discount market price time certain conditions purchase rights may redeemed board whole part price per purchase right purchase rights voting privileges attached automatically trade gilead common stock october october board directors approved amendments rights plan first amendment provided among things increase exercise price right plan extension term plan november october second amendment provides among things increase exercise price right plan extension term rights plan october comprehensive income loss comprehensive income loss comprises net income certain changes stockholders equity excluded net income excluded items comprehensive income loss include changes fair value outstanding effective cash flow hedges changes unrealized gains losses availableforsale securities changes cumulative foreign currency translation account comprehensive income loss years ended december included consolidated statement stockholders equity components comprehensive income loss shown net related taxes underlying assets liabilities held jurisdictions expected generate future tax benefit liability following reclassifications recorded connection net realized gains losses sales securities cash flow hedges previously included comprehensive income loss thousands year ended december net unrealized loss related availableforsale securities net tax benefit respectively net unrealized gain loss related cash flow hedges net tax provision respectively reclassification adjustments net tax benefit provision respectively comprehensive income loss table contents gilead sciences inc notes consolidated financial statementscontinued december balance accumulated comprehensive income loss net taxes reported consolidated balance sheets consists following components thousands december net unrealized loss availableforsale securities net unrealized gain loss cash flow hedges net foreign currency translation gain accumulated comprehensive income loss disclosures segments enterprise related information gilead operates one business segment primarily focuses development commercialization human therapeutics infectious diseases products included one segment major products viread truvada emtriva collectively hiv products ambisome together accounted total product sales years ended december respectively similar economic characteristics including nature products production processes type customers distribution methods regulatory environment product sales consist following thousands year ended december hiv products viread truvada emtriva total hiv products ambisome hepsera vistide daunoxome total product sales table contents gilead sciences inc notes consolidated financial statementscontinued december product sales productrelated contract revenue attributed countries based shipto location royalty nonproduct related contract revenue attributed countries based location collaboration partner certain revenue amounts reclassified geographic regions conform current period presentation following table summarizes total revenues external customers collaboration partners geographic region thousands year ended december united states outside united states france spain united kingdom italy germany switzerland european countries countries total revenues outside united states total revenues december net book value property plant equipment million approximately assets located united states december net book value property plant equipment million approximately assets located united states following table summarizes revenues customers individually accounted total revenues total revenues year ended december cardinal health inc amerisourcebergen corp mckesson corp table contents gilead sciences inc notes consolidated financial statementscontinued december income taxes provision benefit income taxes consisted following thousands year ended december federal current deferred state current deferred foreign current deferred foreign pretax income loss million million million companys foreign subsidiaries generated operating losses reflecting costs building commercial infrastructure europe foreign subsidiaries investment rd efforts cumulative unremitted foreign earnings considered permanently invested outside united states us taxes provided approximately million december residual us tax liability amounts remitted would approximately million difference provision benefit income taxes amount computed applying federal statutory income tax rate income loss provision benefit income taxes explained thousands year ended december income loss provision benefit income taxes tax federal statutory rate state taxes net federal benefit foreign earnings different rates benefit qualified foreign earnings repatriation benefited losses change valuation allowance inprocess rd charge foreign losses different rates provision benefit income taxes tax benefits associated stock option exercises employee stock purchase plan million year ended december benefit credited additional paidin capital table contents gilead sciences inc notes consolidated financial statementscontinued december deferred income taxes reflect net tax effects temporary differences carrying amounts assets liabilities financial reporting purposes amounts used income tax purposes significant components companys deferred tax assets liabilities follows thousands december deferred tax assets net operating loss carryforwards reserves accruals currently deductible depreciation related research credit carryforwards capitalized intangibles capitalized rd expenses net total deferred tax assets valuation allowance valuation allowance total deferred tax assets deferred tax liabilities unrealized gains investments unremitted foreign earnings total deferred tax liabilities net deferred tax assets company valuation allowance december valuation allowance million december valuation allowance decreased million million million years ended december respectively concluded based standard set forth sfas accounting income taxes likely realize benefits related deferred tax assets approximately million valuation allowance december related tax benefits stock option deductions credited additional paidin capital december company us federal net operating loss carryforwards approximately million federal net operating loss carryforwards expire various dates utilized addition company federal tax credit carryforwards approximately million expire utilized utilization net operating losses tax credits may subject annual limitation due ownership change limitations provided internal revenue code similar state provisions annual limitation may result expiration net operating losses credits utilization october ajca signed law ajca allows deduction certain qualified foreign earnings repatriated defined ajca company elected apply provision qualifying earnings repatriation fiscal earnings repatriation resulted one time tax benefit approximately million includes reversal deferred tax liability previously accrued unremitted foreign earnings million december table contents gilead sciences inc notes consolidated financial statementscontinued december deferred compensation plans gilead maintains one retirement savings plan eligible employees may defer compensation income tax purposes section k internal revenue code gilead plan gilead plan employees may contribute eligible annual compensation gilead makes matching contributions gilead plan contribute employees first contributions annual maximum match total matching contribution expense gilead plan million million gilead maintains deferred compensation plan directors officers may defer compensation income tax purposes deferred compensation plan nonqualified deferred compensation plan subject qualification requirements section internal revenue code compensation deferred december subject requirements section internal revenue code plan officers may contribute annual salaries annual bonus directors may contribute annual retainer fee amounts deferred participants deposited rabbi trust recorded noncurrent assets consolidated balance sheets beginning directors may also elect receive portion annual cash retainer phantom shares gives participant right receive amount equal value specified number shares specified period time payable cash shares established plan administrator december issued phantom shares participants elect one several distribution dates available plan receive deferred compensation payment table contents gilead sciences inc notes consolidated financial statementscontinued december quarterly results operations unaudited following amounts thousands except per share amounts st quarter nd quarter rd quarter th quarter total revenues gross profit product sales total costs expenses net income net income per sharebasic net income per sharediluted total revenues gross profit product sales total costs expenses net income net income per sharebasic net income per sharediluted fourth quarter gilead recognized million royalty revenue relating resolution dispute roche fourth quarter gilead recorded onetime tax benefit million related repatriation qualified foreign earnings ajca first quarter gilead recorded pretax gain million related warrants purchase capital stock eyetech completed initial public offering fourth quarter gilead recorded expense million connection makewhole payment convertible senior note holders relation redemption conversion convertible senior notes september gilead implemented twoforone stock split form stock dividends per share amounts periods presented restated reflect stock split table contents gilead sciences inc schedule ii valuation qualifying accounts balance balance beginning charged end period expense deductions period year ended december accounts receivable allowances valuation allowance deferred tax assets year ended december accounts receivable allowances valuation allowance deferred tax assets year ended december accounts receivable allowances valuation allowance deferred tax assets allowances doubtful accounts sales returns cash discounts chargebacks table contents